

Leverett

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2001-2005

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	2	2.1	nc	(nc-nc)	Male	2	1.3	nc	(nc-nc)
Female	1	0.6	nc	(nc-nc)	Female	0	0.9	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	0	0.4	nc	(nc-nc)	Male	0	0.3	nc	(nc-nc)
Female	0	0.3	nc	(nc-nc)	Female	0	0.2	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.1	nc	(nc-nc)	Male	0	1.1	nc	(nc-nc)
Female	5	7.1	70.0	(22.6-163.5)	Female	1	0.8	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity and Pharynx</u>				
Female	0	0.3	nc	(nc-nc)	Male	2	0.9	nc	(nc-nc)
<u>Colon / Rectum</u>					<u>Ovary</u>				
Male	4	3.2	nc	(nc-nc)	Female	3	0.7	nc	(nc-nc)
Female	1	2.2	nc	(nc-nc)	<u>Pancreas</u>				
<u>Esophagus</u>					Male	0	0.6	nc	(nc-nc)
Male	1	0.6	nc	(nc-nc)	Female	1	0.5	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	<u>Prostate</u>				
<u>Hodgkin Lymphoma</u>					Male	11	9.0	122.4	(61.0-219.1)
Male	0	0.2	nc	(nc-nc)	<u>Stomach</u>				
Female	0	0.1	nc	(nc-nc)	Male	0	0.5	nc	(nc-nc)
<u>Kidney and Renal Pelvis</u>					Female	0	0.2	nc	(nc-nc)
Male	0	1.0	nc	(nc-nc)	<u>Testis</u>				
Female	1	0.5	nc	(nc-nc)	Male	0	0.2	nc	(nc-nc)
<u>Larynx</u>					<u>Thyroid</u>				
Male	0	0.4	nc	(nc-nc)	Male	1	0.3	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	Female	0	0.9	nc	(nc-nc)
<u>Leukemia</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	0	0.7	nc	(nc-nc)	Female	2	1.5	nc	(nc-nc)
Female	1	0.4	nc	(nc-nc)	<u>All Sites / Types</u>				
<u>Liver and Intrahepatic Bile Ducts</u>					Male	29	29.6	97.9	(65.6-140.7)
Male	1	0.5	nc	(nc-nc)	Female	20	22.3	89.9	(54.9-138.8)
Female	0	0.1	nc	(nc-nc)					
<u>Lung and Bronchus</u>									
Male	4	4.0	nc	(nc-nc)					
Female	3	2.8	nc	(nc-nc)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Lexington

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2001-2005

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	46	43.2	106.5	(78.0-142.1)	Male	29	24.0	120.7	(80.8-173.3)
Female	15	16.7	90.0	(50.3-148.5)	Female	27	19.5	138.7	(91.4-201.8)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	5	7.3	68.2	(22.0-159.1)	Male	8	6.6	120.6	(51.9-237.7)
Female	8	6.2	128.6	(55.4-253.4)	Female	5	5.1	98.7	(31.8-230.3)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	1	1.2	nc	(nc-nc)	Male	22	21.5	102.1	(64.0-154.6)
Female	139	153.8	90.4	(76.0-106.7)	Female	20	20.8	95.9	(58.6-148.2)
<u>Cervix Uteri</u>					<u>Oral Cavity and Pharynx</u>				
Female	3	5.9	nc	(nc-nc)	Male	10	15.2	65.6	(31.4-120.6)
Female	3	5.9	nc	(nc-nc)	Female	10	7.6	131.5	(63.0-241.9)
<u>Colon / Rectum</u>					<u>Ovary</u>				
Male	52	62.7	83.0	(62.0-108.8)	Female	18	16.6	108.3	(64.2-171.2)
Female	39	64.5	60.5	(43.0-82.7)	Female	18	16.6	108.3	(64.2-171.2)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	8	10.8	74.3	(32.0-146.4)	Male	9	12.6	71.4	(32.6-135.6)
Female	2	3.3	nc	(nc-nc)	Female	8	14.1	56.8	(24.5-112.0)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	2	2.6	nc	(nc-nc)	Male	188	159.8	117.6	(101.4-135.7)
Female	3	1.9	nc	(nc-nc)	Male	188	159.8	117.6	(101.4-135.7)
<u>Kidney and Renal Pelvis</u>					<u>Stomach</u>				
Male	20	18.5	108.3	(66.1-167.2)	Male	4	10.5	nc	(nc-nc)
Female	6	12.1	49.4	(18.1-107.6)	Female	8	6.9	116.1	(50.0-228.8)
<u>Larynx</u>					<u>Testis</u>				
Male	3	6.6	nc	(nc-nc)	Male	1	3.7	nc	(nc-nc)
Female	0	1.9	nc	(nc-nc)	Male	1	3.7	nc	(nc-nc)
<u>Leukemia</u>					<u>Thyroid</u>				
Male	14	13.3	105.6	(57.7-177.2)	Male	6	5.0	119.8	(43.8-260.8)
Female	11	11.0	99.6	(49.7-178.3)	Female	25	15.4	161.9	(104.7-239.0)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	7	8.9	78.5	(31.4-161.7)	Female	23	32.8	70.1	(44.4-105.2)
Female	3	3.4	nc	(nc-nc)	Female	23	32.8	70.1	(44.4-105.2)
<u>Lung and Bronchus</u>					<u>All Sites / Types</u>				
Male	46	80.2	57.4	(42.0-76.5)	Male	514	555.1	92.6	(84.8-101.0)
Female	58	77.5	74.8	(56.8-96.7)	Female	475	540.6	87.9	(80.1-96.1)

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Leyden

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2001-2005

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	0	0.7	nc	(nc-nc)	Male	0	0.5	nc	(nc-nc)
Female	1	0.2	nc	(nc-nc)	Female	0	0.4	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	0	0.2	nc	(nc-nc)	Male	0	0.1	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	Female	0	0.1	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.0	nc	(nc-nc)	Male	1	0.4	nc	(nc-nc)
Female	3	2.8	nc	(nc-nc)	Female	0	0.3	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity and Pharynx</u>				
Female	0	0.1	nc	(nc-nc)	Male	0	0.4	nc	(nc-nc)
<u>Colon / Rectum</u>					<u>Ovary</u>				
Male	2	1.2	nc	(nc-nc)	Female	0	0.3	nc	(nc-nc)
Female	1	0.8	nc	(nc-nc)	<u>Pancreas</u>				
<u>Esophagus</u>					Male	0	0.2	nc	(nc-nc)
Male	1	0.2	nc	(nc-nc)	Female	0	0.2	nc	(nc-nc)
Female	0	0.0	nc	(nc-nc)	<u>Prostate</u>				
<u>Hodgkin Lymphoma</u>					Male	1	3.2	nc	(nc-nc)
Male	0	0.1	nc	(nc-nc)	<u>Stomach</u>				
Female	0	0.1	nc	(nc-nc)	Male	0	0.2	nc	(nc-nc)
<u>Kidney and Renal Pelvis</u>					Female	0	0.1	nc	(nc-nc)
Male	0	0.4	nc	(nc-nc)	<u>Testis</u>				
Female	0	0.2	nc	(nc-nc)	Male	0	0.1	nc	(nc-nc)
<u>Larynx</u>					<u>Thyroid</u>				
Male	0	0.1	nc	(nc-nc)	Male	0	0.1	nc	(nc-nc)
Female	0	0.0	nc	(nc-nc)	Female	0	0.4	nc	(nc-nc)
<u>Leukemia</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	1	0.3	nc	(nc-nc)	Female	0	0.6	nc	(nc-nc)
Female	0	0.2	nc	(nc-nc)	<u>All Sites / Types</u>				
<u>Liver and Intrahepatic Bile Ducts</u>					Male	6	10.9	54.9	(20.1-119.5)
Male	0	0.2	nc	(nc-nc)	Female	6	8.7	68.7	(25.1-149.6)
Female	0	0.0	nc	(nc-nc)					
<u>Lung and Bronchus</u>									
Male	0	1.4	nc	(nc-nc)					
Female	1	1.1	nc	(nc-nc)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Lincoln

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2001-2005

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	3	7.8	nc	(nc-nc)	Male	9	4.8	187.9	(85.7-356.7)
Female	0	2.5	nc	(nc-nc)	Female	4	3.9	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	3	1.6	nc	(nc-nc)	Male	1	1.2	nc	(nc-nc)
Female	1	1.3	nc	(nc-nc)	Female	1	0.8	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.2	nc	(nc-nc)	Male	3	4.2	nc	(nc-nc)
Female	37	27.9	132.4	(93.2-182.5)	Female	1	3.4	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity and Pharynx</u>				
Female	1	1.3	nc	(nc-nc)	Male	4	3.0	nc	(nc-nc)
<u>Colon / Rectum</u>					<u>Ovary</u>				
Male	14	11.6	120.6	(65.9-202.4)	Female	0	2.9	nc	(nc-nc)
Female	13	9.5	137.0	(72.9-234.3)	<u>Pancreas</u>				
<u>Esophagus</u>					Male	1	2.3	nc	(nc-nc)
Male	3	2.0	nc	(nc-nc)	Female	0	2.1	nc	(nc-nc)
Female	0	0.5	nc	(nc-nc)	<u>Prostate</u>				
<u>Hodgkin Lymphoma</u>					Male	32	30.3	105.8	(72.3-149.3)
Male	0	0.7	nc	(nc-nc)	<u>Stomach</u>				
Female	0	0.5	nc	(nc-nc)	Male	0	1.9	nc	(nc-nc)
<u>Kidney and Renal Pelvis</u>					Female	0	1.0	nc	(nc-nc)
Male	3	3.6	nc	(nc-nc)	<u>Testis</u>				
Female	5	2.1	241.0	(77.7-562.5)	Male	3	1.2	nc	(nc-nc)
<u>Larynx</u>					<u>Thyroid</u>				
Male	0	1.3	nc	(nc-nc)	Male	1	1.2	nc	(nc-nc)
Female	0	0.3	nc	(nc-nc)	Female	7	3.7	191.4	(76.7-394.5)
<u>Leukemia</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	2	2.7	nc	(nc-nc)	Female	3	5.9	nc	(nc-nc)
Female	0	1.9	nc	(nc-nc)	<u>All Sites / Types</u>				
<u>Liver and Intrahepatic Bile Ducts</u>					Male	102	105.8	96.4	(78.6-117.0)
Male	2	1.7	nc	(nc-nc)	Female	88	92.7	95.0	(76.2-117.0)
Female	0	0.5	nc	(nc-nc)	<u>Lung and Bronchus</u>				
Male	6	14.8	40.5	(14.8-88.1)	<u>Bladder, Urinary</u>				
Female	12	12.6	95.4	(49.2-166.7)	Male	3	7.8	nc	(nc-nc)
					Female	0	2.5	nc	(nc-nc)

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Littleton

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2001-2005

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	8	8.6	93.0	(40.0-183.2)	Male	5	5.4	92.0	(29.7-214.8)
Female	4	3.1	nc	(nc-nc)	Female	10	4.5	224.1	(107.3-412.2)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	4	1.8	nc	(nc-nc)	Male	3	1.4	nc	(nc-nc)
Female	1	1.4	nc	(nc-nc)	Female	1	0.9	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	1	0.2	nc	(nc-nc)	Male	6	4.8	126.2	(46.1-274.6)
Female	31	32.7	94.7	(64.3-134.4)	Female	5	4.1	121.4	(39.1-283.3)
<u>Cervix Uteri</u>					<u>Oral Cavity and Pharynx</u>				
Female	1	1.5	nc	(nc-nc)	Male	0	3.5	nc	(nc-nc)
<u>Colon / Rectum</u>					<u>Ovary</u>				
Male	16	12.9	123.8	(70.7-201.0)	Female	3	3.5	nc	(nc-nc)
Female	12	12.0	100.3	(51.8-175.2)	<u>Pancreas</u>				
<u>Esophagus</u>					Male	3	2.6	nc	(nc-nc)
Male	2	2.3	nc	(nc-nc)	Female	4	2.6	nc	(nc-nc)
Female	1	0.6	nc	(nc-nc)	<u>Prostate</u>				
<u>Hodgkin Lymphoma</u>					Male	37	33.6	110.0	(77.4-151.6)
Male	2	0.7	nc	(nc-nc)	<u>Stomach</u>				
Female	0	0.5	nc	(nc-nc)	Male	1	2.1	nc	(nc-nc)
<u>Kidney and Renal Pelvis</u>					Female	0	1.3	nc	(nc-nc)
Male	3	4.1	nc	(nc-nc)	<u>Testis</u>				
Female	3	2.4	nc	(nc-nc)	Male	1	1.3	nc	(nc-nc)
<u>Larynx</u>					<u>Thyroid</u>				
Male	0	1.4	nc	(nc-nc)	Male	3	1.3	nc	(nc-nc)
Female	0	0.4	nc	(nc-nc)	Female	3	4.1	nc	(nc-nc)
<u>Leukemia</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	3	2.9	nc	(nc-nc)	Female	5	6.9	72.2	(23.3-168.4)
Female	3	2.3	nc	(nc-nc)	<u>All Sites / Types</u>				
<u>Liver and Intrahepatic Bile Ducts</u>					Male	117	117.8	99.4	(82.2-119.1)
Male	0	2.0	nc	(nc-nc)	Female	105	110.3	95.2	(77.8-115.2)
Female	0	0.6	nc	(nc-nc)					
<u>Lung and Bronchus</u>									
Male	12	16.3	73.7	(38.0-128.7)					
Female	9	14.9	60.6	(27.6-115.0)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Longmeadow

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2001-2005

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	19	21.6	87.9	(52.9-137.2)	Male	18	12.2	148.0	(87.7-233.9)
Female	6	8.2	73.3	(26.8-159.5)	Female	14	9.7	143.9	(78.6-241.4)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	4	3.7	nc	(nc-nc)	Male	3	3.4	nc	(nc-nc)
Female	4	3.1	nc	(nc-nc)	Female	2	2.5	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	3	0.6	nc	(nc-nc)	Male	14	10.9	128.8	(70.4-216.1)
Female	81	76.3	106.1	(84.3-131.9)	Female	14	10.3	135.3	(73.9-227.1)
<u>Cervix Uteri</u>					<u>Oral Cavity and Pharynx</u>				
Female	1	3.0	nc	(nc-nc)	Male	2	7.8	nc	(nc-nc)
<u>Colon / Rectum</u>					<u>Ovary</u>				
Male	25	31.5	79.3	(51.3-117.0)	Female	8	8.3	96.6	(41.6-190.3)
Female	27	32.1	84.1	(55.4-122.4)	<u>Pancreas</u>				
<u>Esophagus</u>					Male	5	6.3	78.8	(25.4-183.9)
Male	6	5.4	110.4	(40.3-240.3)	Female	5	7.0	71.9	(23.2-167.8)
Female	1	1.6	nc	(nc-nc)	<u>Prostate</u>				
<u>Hodgkin Lymphoma</u>					Male	83	80.9	102.6	(81.7-127.2)
Male	2	1.3	nc	(nc-nc)	<u>Stomach</u>				
Female	1	1.0	nc	(nc-nc)	Male	5	5.3	94.9	(30.6-221.4)
<u>Kidney and Renal Pelvis</u>					Female	0	3.5	nc	(nc-nc)
Male	6	9.3	64.5	(23.5-140.4)	<u>Testis</u>				
Female	7	6.0	117.0	(46.9-241.0)	Male	5	1.8	271.4	(87.5-633.3)
<u>Larynx</u>					<u>Thyroid</u>				
Male	1	3.4	nc	(nc-nc)	Male	4	2.5	nc	(nc-nc)
Female	1	0.9	nc	(nc-nc)	Female	9	7.8	115.4	(52.7-219.1)
<u>Leukemia</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	7	6.7	104.6	(41.9-215.5)	Female	19	16.3	116.3	(70.0-181.6)
Female	5	5.5	90.8	(29.2-211.8)	<u>All Sites / Types</u>				
<u>Liver and Intrahepatic Bile Ducts</u>					Male	251	279.6	89.8	(79.0-101.6)
Male	5	4.5	110.3	(35.6-257.5)	Female	247	268.1	92.1	(81.0-104.4)
Female	0	1.7	nc	(nc-nc)					
<u>Lung and Bronchus</u>									
Male	21	39.9	52.7	(32.6-80.5)					
Female	26	37.7	69.0	(45.0-101.1)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Lowell

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2001-2005

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	100	81.8	122.3	(99.5-148.7)	Male	21	53.7	39.1	(24.2-59.8)
Female	29	34.5	84.0	(56.3-120.7)	Female	24	48.7	49.3	(31.6-73.3)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	18	18.6	96.5	(57.2-152.6)	Male	10	13.1	76.3	(36.5-140.3)
Female	15	15.8	94.8	(53.0-156.4)	Female	13	10.5	124.0	(66.0-212.1)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	4	2.4	nc	(nc-nc)	Male	51	47.1	108.2	(80.6-142.3)
Female	271	337.1	80.4	(71.1-90.6)	Female	46	45.7	100.7	(73.7-134.3)
<u>Cervix Uteri</u>					<u>Oral Cavity and Pharynx</u>				
Female	26	16.0	162.7	(106.3-238.4)	Male	68	32.8	207.3	(161.0-262.8)
Female					Female	24	16.7	143.9	(92.2-214.2)
<u>Colon / Rectum</u>					<u>Ovary</u>				
Male	145	123.1	117.8	(99.4-138.6)	Female	35	36.6	95.6	(66.5-132.9)
Female	152	132.2	115.0	(97.4-134.7)	<u>Pancreas</u>				
<u>Esophagus</u>					Male	20	24.4	82.1	(50.1-126.8)
Male	29	21.4	135.2	(90.6-194.2)	Female	32	28.7	111.4	(76.2-157.2)
Female	9	6.7	133.5	(60.9-253.4)	<u>Prostate</u>				
<u>Hodgkin Lymphoma</u>					Male	248	319.5	77.6	(68.3-87.9)
Male	7	9.7	72.4	(29.0-149.2)	<u>Stomach</u>				
Female	6	7.6	79.2	(28.9-172.3)	Male	16	20.4	78.5	(44.8-127.5)
<u>Kidney and Renal Pelvis</u>					Female	14	14.1	99.3	(54.2-166.5)
Male	43	39.2	109.8	(79.5-147.9)	<u>Testis</u>				
Female	34	26.3	129.1	(89.4-180.5)	Male	7	17.9	39.0	(15.6-80.4)
<u>Larynx</u>					<u>Thyroid</u>				
Male	22	13.4	163.9	(102.7-248.2)	Male	9	14.0	64.2	(29.3-121.8)
Female	5	4.0	124.6	(40.2-290.8)	Female	46	44.8	102.8	(75.2-137.1)
<u>Leukemia</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	33	29.8	110.8	(76.3-155.6)	Female	72	70.9	101.5	(79.4-127.8)
Female	27	25.5	106.0	(69.8-154.3)	<u>All Sites / Types</u>				
<u>Liver and Intrahepatic Bile Ducts</u>					Male	1155	1140.4	101.3	(95.5-107.3)
Male	30	18.6	161.0	(108.6-229.9)	Female	1174	1186.3	99.0	(93.4-104.8)
Female	8	7.1	113.2	(48.7-223.0)					
<u>Lung and Bronchus</u>									
Male	192	155.6	123.4	(106.6-142.2)					
Female	188	163.4	115.1	(99.2-132.7)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Ludlow

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2001-2005

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	14	24.8	56.4	(30.8-94.6)	Male	8	15.2	52.7	(22.7-103.8)
Female	4	9.2	nc	(nc-nc)	Female	3	11.7	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	5	4.8	104.4	(33.7-243.7)	Male	4	3.9	nc	(nc-nc)
Female	4	3.7	nc	(nc-nc)	Female	3	2.8	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.7	nc	(nc-nc)	Male	6	13.4	44.9	(16.4-97.7)
Female	90	88.2	102.0	(82.0-125.4)	Female	13	11.9	109.3	(58.2-187.0)
<u>Cervix Uteri</u>					<u>Oral Cavity and Pharynx</u>				
Female	3	3.7	nc	(nc-nc)	Male	4	9.6	nc	(nc-nc)
<u>Colon / Rectum</u>					<u>Ovary</u>				
Male	32	36.9	86.8	(59.4-122.6)	Female	8	9.5	83.9	(36.1-165.4)
Female	31	34.8	89.2	(60.6-126.6)	<u>Pancreas</u>				
<u>Esophagus</u>					Male	7	7.4	95.1	(38.1-195.9)
Male	1	6.4	nc	(nc-nc)	Female	8	7.7	104.5	(45.0-205.9)
Female	1	1.8	nc	(nc-nc)	<u>Prostate</u>				
<u>Hodgkin Lymphoma</u>					Male	96	97.2	98.8	(80.0-120.7)
Male	2	2.2	nc	(nc-nc)	<u>Stomach</u>				
Female	1	1.4	nc	(nc-nc)	Male	5	6.1	81.8	(26.4-191.0)
<u>Kidney and Renal Pelvis</u>					Female	2	3.6	nc	(nc-nc)
Male	18	11.4	157.7	(93.4-249.2)	<u>Testis</u>				
Female	4	7.0	nc	(nc-nc)	Male	4	3.9	nc	(nc-nc)
<u>Larynx</u>					<u>Thyroid</u>				
Male	5	4.0	124.1	(40.0-289.7)	Male	6	3.6	164.6	(60.1-358.3)
Female	0	1.1	nc	(nc-nc)	Female	11	10.0	110.4	(55.0-197.5)
<u>Leukemia</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	12	8.1	147.8	(76.3-258.2)	Female	18	19.0	94.8	(56.2-149.8)
Female	1	6.2	nc	(nc-nc)	<u>All Sites / Types</u>				
<u>Liver and Intrahepatic Bile Ducts</u>					Male	294	336.7	87.3	(77.6-97.9)
Male	6	5.5	109.9	(40.1-239.2)	Female	250	308.0	81.2	(71.4-91.9)
Female	1	1.8	nc	(nc-nc)					
<u>Lung and Bronchus</u>									
Male	46	47.3	97.3	(71.3-129.8)					
Female	23	44.7	51.4	(32.6-77.2)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Lunenburg

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2001-2005

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	10	10.3	96.7	(46.3-177.8)	Male	5	6.6	76.1	(24.5-177.5)
Female	4	3.4	nc	(nc-nc)	Female	3	5.2	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	2	2.1	nc	(nc-nc)	Male	2	1.7	nc	(nc-nc)
Female	2	1.6	nc	(nc-nc)	Female	1	1.1	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.3	nc	(nc-nc)	Male	4	5.7	nc	(nc-nc)
Female	30	38.5	78.0	(52.6-111.3)	Female	6	4.6	130.0	(47.5-283.1)
<u>Cervix Uteri</u>					<u>Oral Cavity and Pharynx</u>				
Female	2	1.8	nc	(nc-nc)	Male	4	4.3	nc	(nc-nc)
<u>Colon / Rectum</u>					<u>Ovary</u>				
Male	13	15.7	83.0	(44.1-141.9)	Female	3	4.0	nc	(nc-nc)
Female	9	13.0	69.3	(31.6-131.5)	<u>Pancreas</u>				
<u>Esophagus</u>					Male	2	3.1	nc	(nc-nc)
Male	5	2.8	180.0	(58.0-420.2)	Female	4	2.8	nc	(nc-nc)
Female	2	0.7	nc	(nc-nc)	<u>Prostate</u>				
<u>Hodgkin Lymphoma</u>					Male	43	41.5	103.7	(75.1-139.7)
Male	0	0.9	nc	(nc-nc)	<u>Stomach</u>				
Female	1	0.6	nc	(nc-nc)	Male	2	2.6	nc	(nc-nc)
<u>Kidney and Renal Pelvis</u>					Female	0	1.3	nc	(nc-nc)
Male	6	5.0	119.8	(43.8-260.8)	<u>Testis</u>				
Female	1	2.8	nc	(nc-nc)	Male	1	1.5	nc	(nc-nc)
<u>Larynx</u>					<u>Thyroid</u>				
Male	2	1.7	nc	(nc-nc)	Male	0	1.6	nc	(nc-nc)
Female	0	0.4	nc	(nc-nc)	Female	3	4.8	nc	(nc-nc)
<u>Leukemia</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	4	3.5	nc	(nc-nc)	Female	6	8.2	73.0	(26.6-158.8)
Female	4	2.4	nc	(nc-nc)	<u>All Sites / Types</u>				
<u>Liver and Intrahepatic Bile Ducts</u>					Male	134	143.3	93.5	(78.4-110.8)
Male	2	2.4	nc	(nc-nc)	Female	107	126.0	84.9	(69.6-102.6)
Female	0	0.7	nc	(nc-nc)					
<u>Lung and Bronchus</u>									
Male	24	19.8	121.3	(77.7-180.5)					
Female	17	17.0	100.1	(58.3-160.3)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Lynn

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2001-2005

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	102	82.9	123.1	(100.3-149.4)	Male	41	51.1	80.2	(57.5-108.8)
Female	33	32.7	101.0	(69.5-141.8)	Female	26	44.8	58.1	(37.9-85.1)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	16	17.2	93.0	(53.1-151.0)	Male	17	13.0	130.5	(76.0-208.9)
Female	22	14.5	151.2	(94.7-228.9)	Female	10	9.9	100.6	(48.1-185.0)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	5	2.3	212.9	(68.6-497.0)	Male	52	45.3	114.8	(85.7-150.5)
Female	277	318.5	87.0	(77.0-97.8)	Female	49	42.8	114.4	(84.6-151.2)
<u>Cervix Uteri</u>					<u>Oral Cavity and Pharynx</u>				
Female	20	14.5	137.8	(84.1-212.9)	Male	40	31.3	127.6	(91.2-173.8)
<u>Colon / Rectum</u>					<u>Ovary</u>				
Male	131	122.7	106.8	(89.3-126.7)	Female	35	34.5	101.4	(70.6-141.0)
Female	118	125.0	94.4	(78.1-113.1)	<u>Pancreas</u>				
<u>Esophagus</u>					Male	22	24.4	90.1	(56.5-136.5)
Male	31	21.1	146.6	(99.6-208.1)	Female	43	27.3	157.8	(114.2-212.5)
Female	9	6.4	140.8	(64.2-267.3)	<u>Prostate</u>				
<u>Hodgkin Lymphoma</u>					Male	270	312.4	86.4	(76.4-97.4)
Male	11	8.2	134.9	(67.2-241.3)	<u>Stomach</u>				
Female	9	6.5	138.9	(63.4-263.6)	Male	37	20.5	180.4	(127.0-248.7)
<u>Kidney and Renal Pelvis</u>					Female	18	13.3	135.8	(80.5-214.7)
Male	37	37.7	98.1	(69.1-135.2)	<u>Testis</u>				
Female	40	24.9	160.7	(114.8-218.9)	Male	8	14.4	55.7	(24.0-109.9)
<u>Larynx</u>					<u>Thyroid</u>				
Male	19	13.1	144.9	(87.2-226.3)	Male	11	12.4	88.6	(44.2-158.6)
Female	9	3.8	235.9	(107.7-447.9)	Female	30	40.2	74.6	(50.3-106.5)
<u>Leukemia</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	42	28.7	146.2	(105.4-197.7)	Female	73	67.5	108.1	(84.7-135.9)
Female	35	23.7	147.7	(102.9-205.5)	<u>All Sites / Types</u>				
<u>Liver and Intrahepatic Bile Ducts</u>					Male	1221	1115.0	109.5	(103.4-115.8)
Male	25	18.0	138.7	(89.7-204.7)	Female	1201	1116.0	107.6	(101.6-113.9)
Female	7	6.7	105.0	(42.1-216.3)					
<u>Lung and Bronchus</u>									
Male	208	155.2	134.0	(116.4-153.5)					
Female	210	155.2	135.3	(117.6-154.9)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Lynnfield

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2001-2005

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	16	17.0	94.3	(53.9-153.2)	Male	13	9.5	136.8	(72.8-234.0)
Female	7	5.5	127.2	(51.0-262.2)	Female	13	6.9	188.2	(100.1-321.8)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	1	2.9	nc	(nc-nc)	Male	2	2.6	nc	(nc-nc)
Female	2	2.2	nc	(nc-nc)	Female	1	1.7	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	1	0.5	nc	(nc-nc)	Male	6	8.5	70.6	(25.8-153.8)
Female	55	54.4	101.1	(76.1-131.6)	Female	7	7.1	98.9	(39.6-203.7)
<u>Cervix Uteri</u>					<u>Oral Cavity and Pharynx</u>				
Female	5	2.2	230.0	(74.1-536.7)	Male	3	6.1	nc	(nc-nc)
<u>Colon / Rectum</u>					<u>Ovary</u>				
Male	24	24.7	97.0	(62.1-144.3)	Female	5	5.8	85.7	(27.6-199.9)
Female	14	20.8	67.4	(36.8-113.1)	<u>Pancreas</u>				
<u>Esophagus</u>					Male	5	5.0	100.4	(32.3-234.2)
Male	8	4.3	186.3	(80.2-367.1)	Female	4	4.6	nc	(nc-nc)
Female	0	1.1	nc	(nc-nc)	<u>Prostate</u>				
<u>Hodgkin Lymphoma</u>					Male	73	64.5	113.2	(88.7-142.3)
Male	3	1.1	nc	(nc-nc)	<u>Stomach</u>				
Female	0	0.7	nc	(nc-nc)	Male	2	4.1	nc	(nc-nc)
<u>Kidney and Renal Pelvis</u>					Female	3	2.1	nc	(nc-nc)
Male	5	7.4	67.8	(21.9-158.2)	<u>Testis</u>				
Female	2	4.2	nc	(nc-nc)	Male	2	1.5	nc	(nc-nc)
<u>Larynx</u>					<u>Thyroid</u>				
Male	2	2.7	nc	(nc-nc)	Male	4	2.0	nc	(nc-nc)
Female	1	0.7	nc	(nc-nc)	Female	3	5.8	nc	(nc-nc)
<u>Leukemia</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	8	5.2	153.1	(65.9-301.6)	Female	6	11.9	50.5	(18.4-109.9)
Female	2	3.6	nc	(nc-nc)	<u>All Sites / Types</u>				
<u>Liver and Intrahepatic Bile Ducts</u>					Male	223	221.0	100.9	(88.1-115.1)
Male	1	3.5	nc	(nc-nc)	Female	176	186.1	94.6	(81.1-109.6)
Female	2	1.1	nc	(nc-nc)					
<u>Lung and Bronchus</u>									
Male	17	31.8	53.4	(31.1-85.5)					
Female	24	26.8	89.4	(57.3-133.1)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Malden

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2001-2005

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	59	56.7	104.0	(79.2-134.2)	Male	23	35.0	65.7	(41.6-98.6)
Female	26	22.9	113.7	(74.3-166.7)	Female	23	30.9	74.5	(47.2-111.8)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	14	11.2	125.5	(68.6-210.6)	Male	8	8.9	89.6	(38.6-176.6)
Female	7	9.6	73.2	(29.3-150.8)	Female	2	6.9	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	1.6	nc	(nc-nc)	Male	29	30.8	94.3	(63.1-135.4)
Female	196	218.7	89.6	(77.5-103.1)	Female	28	29.7	94.3	(62.6-136.3)
<u>Cervix Uteri</u>					<u>Oral Cavity and Pharynx</u>				
Female	10	10.0	100.1	(47.9-184.1)	Male	24	21.1	113.5	(72.7-168.9)
<u>Colon / Rectum</u>					<u>Ovary</u>				
Male	100	83.8	119.4	(97.1-145.2)	Female	22	23.7	93.0	(58.2-140.7)
Female	89	87.3	102.0	(81.9-125.5)	<u>Pancreas</u>				
<u>Esophagus</u>					Male	20	16.6	120.1	(73.4-185.6)
Male	11	14.4	76.2	(38.0-136.4)	Female	10	19.0	52.5	(25.1-96.6)
Female	6	4.5	134.0	(48.9-291.6)	<u>Prostate</u>				
<u>Hodgkin Lymphoma</u>					Male	186	216.4	85.9	(74.0-99.2)
Male	3	5.4	nc	(nc-nc)	<u>Stomach</u>				
Female	3	4.3	nc	(nc-nc)	Male	15	14.0	107.3	(60.0-177.0)
<u>Kidney and Renal Pelvis</u>					Female	12	9.3	129.3	(66.7-225.9)
Male	20	25.7	77.9	(47.5-120.3)	<u>Testis</u>				
Female	12	17.1	70.0	(36.1-122.3)	Male	6	10.1	59.6	(21.8-129.8)
<u>Larynx</u>					<u>Thyroid</u>				
Male	5	9.0	55.6	(17.9-129.8)	Male	8	8.5	93.8	(40.4-184.8)
Female	2	2.6	nc	(nc-nc)	Female	34	27.4	123.9	(85.8-173.2)
<u>Leukemia</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	13	18.9	68.9	(36.6-117.8)	Female	37	46.5	79.6	(56.0-109.7)
Female	17	15.8	107.3	(62.5-171.8)	<u>All Sites / Types</u>				
<u>Liver and Intrahepatic Bile Ducts</u>					Male	753	763.1	98.7	(91.7-106.0)
Male	19	12.2	155.5	(93.6-242.9)	Female	720	770.4	93.5	(86.8-100.5)
Female	7	4.6	150.6	(60.3-310.3)					
<u>Lung and Bronchus</u>									
Male	126	106.8	118.0	(98.3-140.5)					
Female	100	108.3	92.4	(75.1-112.3)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Manchester

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2001-2005

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	7	7.1	98.0	(39.3-202.0)	Male	4	4.2	nc	(nc-nc)
Female	3	2.6	nc	(nc-nc)	Female	5	3.3	152.0	(49.0-354.8)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	4	1.3	nc	(nc-nc)	Male	0	1.1	nc	(nc-nc)
Female	1	1.0	nc	(nc-nc)	Female	0	0.8	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.2	nc	(nc-nc)	Male	3	3.7	nc	(nc-nc)
Female	40	26.0	153.9	(109.9-209.6)	Female	3	3.3	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity and Pharynx</u>				
Female	1	1.0	nc	(nc-nc)	Male	5	2.8	178.0	(57.4-415.5)
<u>Colon / Rectum</u>					Female	3	1.2	nc	(nc-nc)
Male	12	10.6	113.0	(58.3-197.4)	<u>Ovary</u>				
Female	8	9.7	82.6	(35.6-162.7)	Female	2	2.8	nc	(nc-nc)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	1	1.9	nc	(nc-nc)	Male	3	2.1	nc	(nc-nc)
Female	0	0.5	nc	(nc-nc)	Female	2	2.1	nc	(nc-nc)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	0	0.5	nc	(nc-nc)	Male	26	29.1	89.2	(58.3-130.7)
Female	0	0.3	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney and Renal Pelvis</u>					Male	1	1.7	nc	(nc-nc)
Male	1	3.3	nc	(nc-nc)	Female	0	1.0	nc	(nc-nc)
Female	1	2.0	nc	(nc-nc)	<u>Testis</u>				
<u>Larynx</u>					Male	0	0.7	nc	(nc-nc)
Male	0	1.2	nc	(nc-nc)	<u>Thyroid</u>				
Female	0	0.3	nc	(nc-nc)	Male	2	0.9	nc	(nc-nc)
<u>Leukemia</u>					Female	0	2.8	nc	(nc-nc)
Male	6	2.2	269.5	(98.4-586.5)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	3	1.7	nc	(nc-nc)	Female	3	5.7	nc	(nc-nc)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	3	1.6	nc	(nc-nc)	Male	93	96.8	96.1	(77.6-117.7)
Female	0	0.5	nc	(nc-nc)	Female	88	87.8	100.3	(80.4-123.5)
<u>Lung and Bronchus</u>									
Male	7	13.7	51.0	(20.4-105.0)					
Female	6	12.4	48.4	(17.7-105.3)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Mansfield

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2001-2005

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	16	13.7	116.7	(66.7-189.6)	Male	14	10.5	132.8	(72.6-222.9)
Female	13	5.0	262.2	(139.5-448.4)	Female	11	9.7	113.5	(56.6-203.1)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	3	3.9	nc	(nc-nc)	Male	5	2.3	214.1	(69.0-499.6)
Female	2	3.0	nc	(nc-nc)	Female	3	1.5	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.4	nc	(nc-nc)	Male	6	9.0	66.7	(24.3-145.1)
Female	52	62.9	82.7	(61.8-108.5)	Female	6	7.3	82.7	(30.2-179.9)
<u>Cervix Uteri</u>					<u>Oral Cavity and Pharynx</u>				
Female	4	3.6	nc	(nc-nc)	Male	9	6.6	137.4	(62.7-260.8)
<u>Colon / Rectum</u>					<u>Ovary</u>				
Male	27	21.8	124.1	(81.7-180.5)	Female	5	6.5	77.2	(24.9-180.1)
Female	20	19.2	104.0	(63.5-160.6)	<u>Pancreas</u>				
<u>Esophagus</u>					Male	4	4.2	nc	(nc-nc)
Male	9	3.9	233.6	(106.6-443.4)	Female	4	4.1	nc	(nc-nc)
Female	0	1.0	nc	(nc-nc)	<u>Prostate</u>				
<u>Hodgkin Lymphoma</u>					Male	48	55.4	86.7	(63.9-115.0)
Male	1	1.9	nc	(nc-nc)	<u>Stomach</u>				
Female	3	1.5	nc	(nc-nc)	Male	3	3.6	nc	(nc-nc)
<u>Kidney and Renal Pelvis</u>					Female	3	2.0	nc	(nc-nc)
Male	9	7.6	119.2	(54.4-226.3)	<u>Testis</u>				
Female	3	4.3	nc	(nc-nc)	Male	5	3.9	127.8	(41.2-298.2)
<u>Larynx</u>					<u>Thyroid</u>				
Male	1	2.4	nc	(nc-nc)	Male	4	3.1	nc	(nc-nc)
Female	2	0.7	nc	(nc-nc)	Female	12	10.3	116.3	(60.0-203.2)
<u>Leukemia</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	4	5.6	nc	(nc-nc)	Female	9	12.6	71.5	(32.6-135.8)
Female	5	4.3	116.4	(37.5-271.7)	<u>All Sites / Types</u>				
<u>Liver and Intrahepatic Bile Ducts</u>					Male	201	204.7	98.2	(85.1-112.7)
Male	1	3.6	nc	(nc-nc)	Female	203	201.8	100.6	(87.2-115.4)
Female	3	1.1	nc	(nc-nc)					
<u>Lung and Bronchus</u>									
Male	18	26.3	68.4	(40.5-108.1)					
Female	25	24.1	103.7	(67.1-153.1)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Marblehead

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2001-2005

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	29	26.2	110.6	(74.1-158.8)	Male	33	15.4	214.9	(147.9-301.9)
Female	9	9.4	96.0	(43.8-182.3)	Female	24	12.4	193.1	(123.7-287.3)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	6	4.8	126.2	(46.1-274.8)	Male	5	4.1	121.2	(39.0-282.8)
Female	5	3.9	129.1	(41.6-301.4)	Female	0	2.9	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.8	nc	(nc-nc)	Male	15	13.6	110.4	(61.7-182.1)
Female	114	95.5	119.4	(98.5-143.5)	Female	12	12.2	98.6	(50.9-172.3)
<u>Cervix Uteri</u>					<u>Oral Cavity and Pharynx</u>				
Female	5	4.0	124.4	(40.1-290.3)	Male	6	10.0	59.7	(21.8-130.0)
<u>Colon / Rectum</u>					<u>Ovary</u>				
Male	49	38.8	126.2	(93.4-166.9)	Female	3	10.2	nc	(nc-nc)
Female	41	35.9	114.2	(82.0-155.0)	<u>Pancreas</u>				
<u>Esophagus</u>					<u>Prostate</u>				
Male	2	6.8	nc	(nc-nc)	Male	119	102.7	115.9	(96.0-138.7)
Female	1	1.8	nc	(nc-nc)	<u>Stomach</u>				
<u>Hodgkin Lymphoma</u>					<u>Testis</u>				
Male	1	1.8	nc	(nc-nc)	Male	4	2.7	nc	(nc-nc)
Female	1	1.4	nc	(nc-nc)	<u>Thyroid</u>				
<u>Kidney and Renal Pelvis</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	10	11.9	84.3	(40.3-155.0)	Female	11	20.5	53.6	(26.7-95.9)
Female	4	7.2	nc	(nc-nc)	<u>All Sites / Types</u>				
<u>Larynx</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	4	4.3	nc	(nc-nc)	Female	11	20.5	53.6	(26.7-95.9)
Female	1	1.1	nc	(nc-nc)	<u>All Sites / Types</u>				
<u>Leukemia</u>					<u>All Sites / Types</u>				
Male	11	8.3	132.8	(66.2-237.7)	Male	382	350.0	109.1	(98.5-120.6)
Female	3	6.4	nc	(nc-nc)	Female	323	323.3	99.9	(89.3-111.4)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	5	5.8	86.9	(28.0-202.7)	<u>All Sites / Types</u>				
Female	2	1.9	nc	(nc-nc)	<u>All Sites / Types</u>				
<u>Lung and Bronchus</u>					<u>All Sites / Types</u>				
Male	30	49.6	60.5	(40.8-86.4)	<u>All Sites / Types</u>				
Female	42	45.1	93.2	(67.2-126.0)	<u>All Sites / Types</u>				

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Marion

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2001-2005

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	2	7.6	nc	(nc-nc)	Male	3	4.3	nc	(nc-nc)
Female	3	2.7	nc	(nc-nc)	Female	7	3.3	214.6	(86.0-442.3)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	3	1.3	nc	(nc-nc)	Male	0	1.2	nc	(nc-nc)
Female	2	1.0	nc	(nc-nc)	Female	0	0.8	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.2	nc	(nc-nc)	Male	2	3.8	nc	(nc-nc)
Female	19	25.6	74.3	(44.7-116.0)	Female	5	3.4	147.4	(47.5-344.1)
<u>Cervix Uteri</u>					<u>Oral Cavity and Pharynx</u>				
Female	1	1.0	nc	(nc-nc)	Male	1	2.7	nc	(nc-nc)
<u>Colon / Rectum</u>					<u>Ovary</u>				
Male	7	11.1	62.8	(25.2-129.4)	Female	1	2.8	nc	(nc-nc)
Female	13	10.2	127.1	(67.6-217.4)	<u>Pancreas</u>				
<u>Esophagus</u>					<u>Prostate</u>				
Male	0	1.9	nc	(nc-nc)	Male	22	29.1	75.7	(47.4-114.6)
Female	0	0.5	nc	(nc-nc)	<u>Stomach</u>				
<u>Hodgkin Lymphoma</u>					<u>Testis</u>				
Male	2	0.5	nc	(nc-nc)	Male	0	0.7	nc	(nc-nc)
Female	0	0.3	nc	(nc-nc)	<u>Thyroid</u>				
<u>Kidney and Renal Pelvis</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	3	3.3	nc	(nc-nc)	Female	9	5.6	160.8	(73.4-305.3)
Female	2	2.0	nc	(nc-nc)	<u>All Sites / Types</u>				
<u>Larynx</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	1	1.2	nc	(nc-nc)	Male	75	99.5	75.4	(59.3-94.5)
Female	1	0.3	nc	(nc-nc)	Female	87	88.8	98.0	(78.5-120.9)
<u>Leukemia</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	1	2.3	nc	(nc-nc)	<u>All Sites / Types</u>				
Female	2	1.8	nc	(nc-nc)	Male	75	99.5	75.4	(59.3-94.5)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	1	1.6	nc	(nc-nc)	Female	87	88.8	98.0	(78.5-120.9)
Female	1	0.5	nc	(nc-nc)	<u>All Sites / Types</u>				
<u>Lung and Bronchus</u>					<u>All Sites / Types</u>				
Male	13	14.3	90.8	(48.3-155.2)	Male	75	99.5	75.4	(59.3-94.5)
Female	9	12.8	70.6	(32.2-134.0)	Female	87	88.8	98.0	(78.5-120.9)

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Marlborough

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2001-2005

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	26	34.8	74.7	(48.8-109.5)	Male	12	22.6	53.1	(27.4-92.7)
Female	12	13.6	88.4	(45.6-154.4)	Female	22	19.3	113.7	(71.2-172.2)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	9	7.4	121.6	(55.5-230.9)	Male	5	5.6	89.1	(28.7-208.0)
Female	8	6.0	132.7	(57.1-261.4)	Female	4	4.1	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	1.0	nc	(nc-nc)	Male	13	19.7	66.0	(35.1-112.9)
Female	148	137.4	107.7	(91.0-126.5)	Female	17	17.9	95.2	(55.4-152.4)
<u>Cervix Uteri</u>					<u>Oral Cavity and Pharynx</u>				
Female	5	6.5	77.3	(24.9-180.5)	Male	17	14.1	120.8	(70.3-193.4)
<u>Colon / Rectum</u>					<u>Ovary</u>				
Male	47	52.5	89.5	(65.7-119.0)	Female	16	14.7	108.9	(62.2-176.9)
Female	40	52.1	76.8	(54.8-104.5)	<u>Pancreas</u>				
<u>Esophagus</u>					Male	5	10.4	48.0	(15.5-112.1)
Male	9	9.2	98.3	(44.9-186.6)	Female	17	11.3	150.6	(87.7-241.2)
Female	4	2.6	nc	(nc-nc)	<u>Prostate</u>				
<u>Hodgkin Lymphoma</u>					Male	120	136.1	88.2	(73.1-105.4)
Male	4	3.5	nc	(nc-nc)	<u>Stomach</u>				
Female	5	2.6	192.6	(62.1-449.4)	Male	6	8.7	69.0	(25.2-150.2)
<u>Kidney and Renal Pelvis</u>					Female	6	5.5	108.2	(39.5-235.5)
Male	16	16.7	95.9	(54.8-155.8)	<u>Testis</u>				
Female	11	10.4	105.5	(52.6-188.7)	Male	4	6.6	nc	(nc-nc)
<u>Larynx</u>					<u>Thyroid</u>				
Male	4	5.8	nc	(nc-nc)	Male	11	5.7	191.8	(95.6-343.2)
Female	0	1.6	nc	(nc-nc)	Female	25	17.8	140.8	(91.1-207.9)
<u>Leukemia</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	8	12.0	66.5	(28.6-131.0)	Female	26	29.1	89.4	(58.4-130.9)
Female	7	9.7	71.9	(28.8-148.2)	<u>All Sites / Types</u>				
<u>Liver and Intrahepatic Bile Ducts</u>					Male	424	481.4	88.1	(79.9-96.9)
Male	10	7.9	126.0	(60.3-231.7)	Female	472	472.4	99.9	(91.1-109.3)
Female	2	2.8	nc	(nc-nc)					
<u>Lung and Bronchus</u>									
Male	74	65.9	112.3	(88.2-141.0)					
Female	56	64.2	87.3	(65.9-113.3)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Marshfield

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2001-2005

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	25	22.1	113.2	(73.2-167.1)	Male	25	14.8	168.5	(109.0-248.8)
Female	12	7.9	152.2	(78.5-265.8)	Female	13	12.6	103.3	(54.9-176.6)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	10	5.0	201.9	(96.7-371.4)	Male	7	3.7	191.6	(76.8-394.8)
Female	4	3.9	nc	(nc-nc)	Female	4	2.4	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.7	nc	(nc-nc)	Male	15	12.8	117.0	(65.5-193.0)
Female	103	92.7	111.1	(90.7-134.8)	Female	7	10.8	64.9	(26.0-133.7)
<u>Cervix Uteri</u>					<u>Oral Cavity and Pharynx</u>				
Female	2	4.4	nc	(nc-nc)	Male	12	9.9	121.0	(62.5-211.5)
<u>Colon / Rectum</u>					<u>Ovary</u>				
Male	39	34.1	114.4	(81.3-156.4)	Female	12	9.7	123.9	(63.9-216.4)
Female	33	29.5	111.7	(76.9-156.9)	<u>Pancreas</u>				
<u>Esophagus</u>					Male	7	6.8	103.1	(41.3-212.4)
Male	6	6.2	97.2	(35.5-211.6)	Female	4	6.4	nc	(nc-nc)
Female	0	1.5	nc	(nc-nc)	<u>Prostate</u>				
<u>Hodgkin Lymphoma</u>					Male	145	94.1	154.1	(130.0-181.3)
Male	2	2.1	nc	(nc-nc)	<u>Stomach</u>				
Female	2	1.6	nc	(nc-nc)	Male	5	5.5	91.0	(29.3-212.3)
<u>Kidney and Renal Pelvis</u>					Female	3	3.0	nc	(nc-nc)
Male	10	11.3	88.3	(42.3-162.4)	<u>Testis</u>				
Female	2	6.6	nc	(nc-nc)	Male	6	3.7	160.7	(58.7-349.8)
<u>Larynx</u>					<u>Thyroid</u>				
Male	3	3.9	nc	(nc-nc)	Male	2	3.8	nc	(nc-nc)
Female	0	1.1	nc	(nc-nc)	Female	13	12.1	107.2	(57.0-183.4)
<u>Leukemia</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	8	7.8	102.8	(44.3-202.6)	Female	25	20.0	124.8	(80.7-184.2)
Female	6	5.8	103.7	(37.9-225.8)	<u>All Sites / Types</u>				
<u>Liver and Intrahepatic Bile Ducts</u>					Male	412	319.2	129.1	(116.9-142.2)
Male	4	5.5	nc	(nc-nc)	Female	311	298.8	104.1	(92.8-116.3)
Female	0	1.6	nc	(nc-nc)					
<u>Lung and Bronchus</u>									
Male	55	43.1	127.7	(96.2-166.2)					
Female	41	39.6	103.5	(74.3-140.4)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Mashpee

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2001-2005

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	30	19.9	150.8	(101.8-215.4)	Male	13	10.8	120.0	(63.8-205.3)
Female	5	6.8	73.9	(23.8-172.5)	Female	11	8.4	131.5	(65.5-235.3)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	5	3.3	151.8	(48.9-354.3)	Male	4	3.0	nc	(nc-nc)
Female	3	2.7	nc	(nc-nc)	Female	4	2.0	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	1	0.6	nc	(nc-nc)	Male	15	9.7	154.2	(86.3-254.4)
Female	92	63.5	144.9	(116.8-177.7)	Female	6	8.5	70.7	(25.8-153.8)
<u>Cervix Uteri</u>					<u>Oral Cavity and Pharynx</u>				
Female	1	2.6	nc	(nc-nc)	Male	6	6.7	90.2	(32.9-196.3)
<u>Colon / Rectum</u>					<u>Ovary</u>				
Male	32	28.5	112.3	(76.8-158.5)	Female	6	6.8	87.8	(32.1-191.1)
Female	19	24.8	76.5	(46.0-119.4)	<u>Pancreas</u>				
<u>Esophagus</u>					Male	5	5.7	87.2	(28.1-203.4)
Male	9	4.9	183.8	(83.9-348.9)	Female	8	5.5	144.6	(62.3-285.0)
Female	3	1.3	nc	(nc-nc)	<u>Prostate</u>				
<u>Hodgkin Lymphoma</u>					Male	100	74.8	133.7	(108.8-162.6)
Male	1	1.3	nc	(nc-nc)	<u>Stomach</u>				
Female	1	1.0	nc	(nc-nc)	Male	3	4.8	nc	(nc-nc)
<u>Kidney and Renal Pelvis</u>					Female	3	2.6	nc	(nc-nc)
Male	8	8.3	96.1	(41.4-189.4)	<u>Testis</u>				
Female	4	5.1	nc	(nc-nc)	Male	2	1.9	nc	(nc-nc)
<u>Larynx</u>					<u>Thyroid</u>				
Male	5	3.0	164.9	(53.1-384.8)	Male	2	2.3	nc	(nc-nc)
Female	1	0.8	nc	(nc-nc)	Female	5	7.1	70.8	(22.8-165.3)
<u>Leukemia</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	8	6.0	133.1	(57.3-262.2)	Female	16	13.9	115.2	(65.8-187.0)
Female	9	4.4	204.1	(93.1-387.5)	<u>All Sites / Types</u>				
<u>Liver and Intrahepatic Bile Ducts</u>					Male	315	255.3	123.4	(110.1-137.8)
Male	3	4.0	nc	(nc-nc)	Female	241	222.3	108.4	(95.2-123.0)
Female	0	1.3	nc	(nc-nc)					
<u>Lung and Bronchus</u>									
Male	40	37.5	106.7	(76.2-145.2)					
Female	32	32.9	97.1	(66.4-137.1)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Mattapoisett

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2001-2005

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	5	8.8	56.9	(18.4-132.9)	Male	9	5.1	177.7	(81.1-337.4)
Female	1	3.1	nc	(nc-nc)	Female	6	3.9	152.2	(55.6-331.3)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	1	1.5	nc	(nc-nc)	Male	1	1.4	nc	(nc-nc)
Female	1	1.2	nc	(nc-nc)	Female	0	1.0	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.3	nc	(nc-nc)	Male	1	4.5	nc	(nc-nc)
Female	31	30.9	100.3	(68.2-142.4)	Female	3	4.0	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity and Pharynx</u>				
Female	0	1.2	nc	(nc-nc)	Male	1	3.3	nc	(nc-nc)
<u>Colon / Rectum</u>					<u>Ovary</u>				
Male	19	12.9	147.4	(88.7-230.3)	Female	3	3.3	nc	(nc-nc)
Female	12	11.8	101.5	(52.4-177.4)	<u>Pancreas</u>				
<u>Esophagus</u>					Male	3	2.6	nc	(nc-nc)
Male	1	2.3	nc	(nc-nc)	Female	1	2.6	nc	(nc-nc)
Female	2	0.6	nc	(nc-nc)	<u>Prostate</u>				
<u>Hodgkin Lymphoma</u>					Male	28	35.0	80.1	(53.2-115.8)
Male	0	0.6	nc	(nc-nc)	<u>Stomach</u>				
Female	1	0.4	nc	(nc-nc)	Male	1	2.1	nc	(nc-nc)
<u>Kidney and Renal Pelvis</u>					Female	1	1.2	nc	(nc-nc)
Male	6	3.9	152.9	(55.8-332.8)	<u>Testis</u>				
Female	3	2.4	nc	(nc-nc)	Male	0	0.9	nc	(nc-nc)
<u>Larynx</u>					<u>Thyroid</u>				
Male	0	1.4	nc	(nc-nc)	Male	1	1.1	nc	(nc-nc)
Female	1	0.4	nc	(nc-nc)	Female	2	3.3	nc	(nc-nc)
<u>Leukemia</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	6	2.7	221.3	(80.8-481.7)	Female	6	6.8	88.6	(32.4-192.9)
Female	1	2.1	nc	(nc-nc)	<u>All Sites / Types</u>				
<u>Liver and Intrahepatic Bile Ducts</u>					Male	108	117.1	92.2	(75.7-111.4)
Male	2	1.9	nc	(nc-nc)	Female	100	105.6	94.7	(77.0-115.1)
Female	0	0.6	nc	(nc-nc)					
<u>Lung and Bronchus</u>									
Male	13	16.7	77.8	(41.4-133.0)					
Female	17	15.1	112.4	(65.5-180.0)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Maynard

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2001-2005

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	7	10.1	69.0	(27.6-142.2)	Male	4	6.5	nc	(nc-nc)
Female	6	4.1	147.6	(53.9-321.3)	Female	8	5.7	139.4	(60.0-274.7)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	3	2.1	nc	(nc-nc)	Male	0	1.6	nc	(nc-nc)
Female	1	1.8	nc	(nc-nc)	Female	1	1.2	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.3	nc	(nc-nc)	Male	6	5.6	106.4	(38.9-231.6)
Female	42	41.6	101.0	(72.8-136.6)	Female	10	5.4	186.7	(89.4-343.4)
<u>Cervix Uteri</u>					<u>Oral Cavity and Pharynx</u>				
Female	4	1.9	nc	(nc-nc)	Male	2	4.1	nc	(nc-nc)
<u>Colon / Rectum</u>					<u>Ovary</u>				
Male	8	15.2	52.5	(22.6-103.4)	Female	8	4.4	180.7	(77.8-356.0)
Female	10	15.6	64.3	(30.8-118.3)	<u>Pancreas</u>				
<u>Esophagus</u>					Male	3	3.0	nc	(nc-nc)
Male	3	2.7	nc	(nc-nc)	Female	5	3.4	148.2	(47.8-345.8)
Female	0	0.8	nc	(nc-nc)	<u>Prostate</u>				
<u>Hodgkin Lymphoma</u>					Male	30	39.4	76.2	(51.4-108.7)
Male	0	0.9	nc	(nc-nc)	<u>Stomach</u>				
Female	1	0.7	nc	(nc-nc)	Male	3	2.5	nc	(nc-nc)
<u>Kidney and Renal Pelvis</u>					Female	3	1.6	nc	(nc-nc)
Male	5	4.8	103.9	(33.5-242.4)	<u>Testis</u>				
Female	6	3.2	190.4	(69.5-414.5)	Male	0	1.6	nc	(nc-nc)
<u>Larynx</u>					<u>Thyroid</u>				
Male	2	1.7	nc	(nc-nc)	Male	2	1.6	nc	(nc-nc)
Female	0	0.5	nc	(nc-nc)	Female	4	5.2	nc	(nc-nc)
<u>Leukemia</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	3	3.4	nc	(nc-nc)	Female	10	8.8	113.3	(54.3-208.5)
Female	4	2.9	nc	(nc-nc)	<u>All Sites / Types</u>				
<u>Liver and Intrahepatic Bile Ducts</u>					Male	118	138.8	85.0	(70.4-101.8)
Male	2	2.3	nc	(nc-nc)	Female	153	141.9	107.9	(91.4-126.4)
Female	0	0.8	nc	(nc-nc)					
<u>Lung and Bronchus</u>									
Male	20	19.1	104.8	(64.0-161.8)					
Female	16	19.5	82.3	(47.0-133.6)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Medfield

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2001-2005

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	13	10.4	125.1	(66.5-213.9)	Male	8	7.1	112.6	(48.5-222.0)
Female	6	3.7	162.4	(59.3-353.6)	Female	11	5.9	187.0	(93.2-334.6)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	4	2.5	nc	(nc-nc)	Male	2	1.7	nc	(nc-nc)
Female	2	1.9	nc	(nc-nc)	Female	2	1.1	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.3	nc	(nc-nc)	Male	6	6.2	97.4	(35.6-212.0)
Female	48	43.8	109.5	(80.7-145.2)	Female	3	5.1	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity and Pharynx</u>				
Female	2	2.1	nc	(nc-nc)	Male	8	4.8	167.1	(71.9-329.2)
<u>Colon / Rectum</u>					<u>Ovary</u>				
Male	18	16.1	111.5	(66.0-176.2)	Female	6	4.5	132.1	(48.2-287.5)
Female	17	14.1	120.8	(70.3-193.5)	<u>Pancreas</u>				
<u>Esophagus</u>					Male				
Male	2	2.9	nc	(nc-nc)	Male	4	3.2	nc	(nc-nc)
Female	2	0.7	nc	(nc-nc)	Female	1	3.0	nc	(nc-nc)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	2	1.0	nc	(nc-nc)	Male	59	43.9	134.4	(102.3-173.4)
Female	0	0.7	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney and Renal Pelvis</u>					Male				
Male	4	5.4	nc	(nc-nc)	Male	1	2.6	nc	(nc-nc)
Female	3	3.1	nc	(nc-nc)	Female	2	1.4	nc	(nc-nc)
<u>Larynx</u>					<u>Testis</u>				
Male	0	1.9	nc	(nc-nc)	Male	1	1.7	nc	(nc-nc)
Female	0	0.5	nc	(nc-nc)	<u>Thyroid</u>				
<u>Leukemia</u>					Male				
Male	3	3.8	nc	(nc-nc)	Male	3	1.8	nc	(nc-nc)
Female	2	2.8	nc	(nc-nc)	Female	8	5.7	140.8	(60.6-277.5)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	3	2.6	nc	(nc-nc)	Female	9	9.2	98.2	(44.8-186.5)
Female	0	0.8	nc	(nc-nc)	<u>All Sites / Types</u>				
<u>Lung and Bronchus</u>					Male				
Male	18	20.4	88.4	(52.4-139.7)	Male	170	150.9	112.7	(96.4-130.9)
Female	20	18.2	109.9	(67.1-169.8)	Female	151	140.5	107.5	(91.0-126.0)

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Medford

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2001-2005

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	69	67.1	102.8	(80.0-130.1)	Male	32	37.8	84.7	(57.9-119.6)
Female	41	27.5	149.0	(106.9-202.2)	Female	25	33.1	75.5	(48.9-111.5)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	8	11.6	69.2	(29.8-136.3)	Male	9	10.2	88.1	(40.2-167.3)
Female	12	10.4	115.9	(59.8-202.5)	Female	10	8.4	119.5	(57.2-219.8)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	1	1.8	nc	(nc-nc)	Male	33	33.9	97.5	(67.1-136.9)
Female	283	244.2	115.9	(102.8-130.2)	Female	38	34.8	109.2	(77.3-149.9)
<u>Cervix Uteri</u>					<u>Oral Cavity and Pharynx</u>				
Female	5	10.2	49.2	(15.9-114.8)	Male	21	22.6	92.9	(57.5-142.0)
Female					Female	12	12.4	96.8	(50.0-169.2)
<u>Colon / Rectum</u>					<u>Ovary</u>				
Male	104	96.6	107.7	(88.0-130.4)	Female	19	26.8	70.9	(42.7-110.7)
Female	108	105.6	102.3	(83.9-123.5)	<u>Pancreas</u>				
<u>Esophagus</u>					Male	21	19.3	108.6	(67.2-166.0)
Male	18	16.4	110.0	(65.1-173.8)	Female	16	23.1	69.1	(39.5-112.2)
Female	6	5.4	110.8	(40.5-241.2)	<u>Prostate</u>				
<u>Hodgkin Lymphoma</u>					Male	223	243.1	91.7	(80.1-104.6)
Male	8	5.2	153.5	(66.1-302.5)	<u>Stomach</u>				
Female	4	4.3	nc	(nc-nc)	Male	17	16.4	104.0	(60.5-166.4)
<u>Kidney and Renal Pelvis</u>					Female	18	11.3	159.0	(94.2-251.3)
Male	21	28.1	74.7	(46.2-114.2)	<u>Testis</u>				
Female	16	19.8	80.7	(46.1-131.1)	Male	9	8.8	102.1	(46.6-193.8)
<u>Larynx</u>					<u>Thyroid</u>				
Male	16	10.0	159.3	(91.0-258.7)	Male	8	8.3	96.4	(41.5-189.9)
Female	4	3.0	nc	(nc-nc)	Female	36	27.2	132.2	(92.6-183.0)
<u>Leukemia</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	19	20.9	90.7	(54.6-141.7)	Female	65	52.1	124.8	(96.3-159.0)
Female	20	18.3	109.5	(66.8-169.1)	<u>All Sites / Types</u>				
<u>Liver and Intrahepatic Bile Ducts</u>					Male	884	860.1	102.8	(96.1-109.8)
Male	18	13.3	134.9	(79.9-213.2)	Female	929	883.6	105.1	(98.5-112.1)
Female	8	5.5	145.1	(62.5-286.0)					
<u>Lung and Bronchus</u>									
Male	152	124.4	122.2	(103.5-143.2)					
Female	111	128.4	86.5	(71.1-104.1)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Medway

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2001-2005

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	9	9.7	92.5	(42.2-175.6)	Male	5	6.8	74.0	(23.9-172.8)
Female	5	3.8	131.4	(42.3-306.6)	Female	9	6.0	149.1	(68.0-283.1)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	2	2.4	nc	(nc-nc)	Male	1	1.6	nc	(nc-nc)
Female	0	1.9	nc	(nc-nc)	Female	2	1.2	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	1	0.3	nc	(nc-nc)	Male	10	5.8	171.5	(82.1-315.3)
Female	39	42.7	91.3	(64.9-124.8)	Female	5	5.2	96.9	(31.2-226.2)
<u>Cervix Uteri</u>					<u>Oral Cavity and Pharynx</u>				
Female	5	2.1	234.8	(75.7-547.8)	Male	5	4.3	115.3	(37.2-269.2)
<u>Colon / Rectum</u>					<u>Ovary</u>				
Male	16	15.1	106.3	(60.7-172.6)	Female	5	4.5	112.0	(36.1-261.4)
Female	20	14.6	136.7	(83.5-211.2)	<u>Pancreas</u>				
<u>Esophagus</u>					Male	7	3.0	235.6	(94.4-485.4)
Male	2	2.7	nc	(nc-nc)	Female	1	3.1	nc	(nc-nc)
Female	0	0.7	nc	(nc-nc)	<u>Prostate</u>				
<u>Hodgkin Lymphoma</u>					Male	54	39.6	136.4	(102.5-178.0)
Male	3	1.0	nc	(nc-nc)	<u>Stomach</u>				
Female	2	0.8	nc	(nc-nc)	Male	1	2.4	nc	(nc-nc)
<u>Kidney and Renal Pelvis</u>					Female	2	1.5	nc	(nc-nc)
Male	6	5.0	119.3	(43.6-259.7)	<u>Testis</u>				
Female	0	3.1	nc	(nc-nc)	Male	2	1.9	nc	(nc-nc)
<u>Larynx</u>					<u>Thyroid</u>				
Male	0	1.7	nc	(nc-nc)	Male	2	1.8	nc	(nc-nc)
Female	0	0.5	nc	(nc-nc)	Female	8	5.9	135.9	(58.5-267.8)
<u>Leukemia</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	3	3.6	nc	(nc-nc)	Female	12	8.7	137.3	(70.9-239.9)
Female	1	3.0	nc	(nc-nc)	<u>All Sites / Types</u>				
<u>Liver and Intrahepatic Bile Ducts</u>					Male	151	140.0	107.9	(91.4-126.5)
Male	0	2.4	nc	(nc-nc)	Female	148	140.9	105.0	(88.8-123.4)
Female	0	0.8	nc	(nc-nc)					
<u>Lung and Bronchus</u>									
Male	13	18.8	69.3	(36.9-118.5)					
Female	22	18.2	120.7	(75.6-182.8)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Melrose

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2001-2005

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	26	32.1	81.0	(52.9-118.7)	Male	29	18.8	154.5	(103.4-221.9)
Female	15	13.3	113.2	(63.3-186.7)	Female	24	16.3	147.1	(94.2-218.8)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	2	5.8	nc	(nc-nc)	Male	6	5.0	120.2	(43.9-261.6)
Female	8	5.1	156.6	(67.4-308.6)	Female	2	4.0	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	1	0.9	nc	(nc-nc)	Male	23	16.7	138.0	(87.5-207.2)
Female	112	122.0	91.8	(75.6-110.4)	Female	13	16.8	77.3	(41.1-132.2)
<u>Cervix Uteri</u>					<u>Oral Cavity and Pharynx</u>				
Female	4	5.1	nc	(nc-nc)	Male	14	11.6	120.3	(65.7-201.9)
<u>Colon / Rectum</u>					<u>Ovary</u>				
Male	53	47.0	112.8	(84.5-147.5)	Female	8	13.2	60.4	(26.0-119.1)
Female	50	51.3	97.4	(72.3-128.5)	<u>Pancreas</u>				
<u>Esophagus</u>					Male	7	9.4	74.6	(29.9-153.7)
Male	5	8.0	62.1	(20.0-145.0)	Female	7	11.2	62.7	(25.1-129.1)
Female	3	2.6	nc	(nc-nc)	<u>Prostate</u>				
<u>Hodgkin Lymphoma</u>					Male	146	119.0	122.7	(103.6-144.3)
Male	4	2.4	nc	(nc-nc)	<u>Stomach</u>				
Female	2	1.9	nc	(nc-nc)	Male	10	7.9	127.0	(60.8-233.5)
<u>Kidney and Renal Pelvis</u>					Female	6	5.5	109.0	(39.8-237.2)
Male	20	14.0	142.6	(87.1-220.3)	<u>Testis</u>				
Female	12	9.7	123.8	(63.9-216.3)	Male	3	4.0	nc	(nc-nc)
<u>Larynx</u>					<u>Thyroid</u>				
Male	2	5.0	nc	(nc-nc)	Male	4	4.2	nc	(nc-nc)
Female	1	1.5	nc	(nc-nc)	Female	13	13.6	95.5	(50.8-163.4)
<u>Leukemia</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	10	10.2	97.8	(46.8-179.9)	Female	14	25.8	54.2	(29.6-90.9)
Female	5	9.0	55.8	(18.0-130.3)	<u>All Sites / Types</u>				
<u>Liver and Intrahepatic Bile Ducts</u>					Male	461	419.3	110.0	(100.1-120.5)
Male	7	6.8	103.6	(41.5-213.4)	Female	414	433.3	95.5	(86.6-105.2)
Female	4	2.7	nc	(nc-nc)					
<u>Lung and Bronchus</u>									
Male	56	59.4	94.3	(71.2-122.4)					
Female	73	61.6	118.6	(92.9-149.1)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Mendon

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2001-2005

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	3	4.5	nc	(nc-nc)	Male	6	3.2	187.3	(68.4-407.8)
Female	2	1.5	nc	(nc-nc)	Female	3	2.6	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	1	1.1	nc	(nc-nc)	Male	1	0.8	nc	(nc-nc)
Female	1	0.8	nc	(nc-nc)	Female	2	0.5	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.1	nc	(nc-nc)	Male	2	2.7	nc	(nc-nc)
Female	18	18.8	95.7	(56.7-151.2)	Female	4	2.2	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity and Pharynx</u>				
Female	2	0.9	nc	(nc-nc)	Male	1	2.1	nc	(nc-nc)
<u>Colon / Rectum</u>					<u>Ovary</u>				
Male	6	7.0	85.2	(31.1-185.4)	Female	0	1.9	nc	(nc-nc)
Female	6	5.9	101.4	(37.0-220.7)	<u>Pancreas</u>				
<u>Esophagus</u>					<u>Prostate</u>				
Male	1	1.3	nc	(nc-nc)	Male	21	18.7	112.1	(69.3-171.3)
Female	0	0.3	nc	(nc-nc)	<u>Stomach</u>				
<u>Hodgkin Lymphoma</u>					<u>Testis</u>				
Male	2	0.5	nc	(nc-nc)	Male	1	0.9	nc	(nc-nc)
Female	0	0.4	nc	(nc-nc)	<u>Thyroid</u>				
<u>Kidney and Renal Pelvis</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	2	2.4	nc	(nc-nc)	Female	1	3.9	nc	(nc-nc)
Female	0	1.3	nc	(nc-nc)	<u>All Sites / Types</u>				
<u>Larynx</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	1	0.8	nc	(nc-nc)	Male	66	65.7	100.5	(77.7-127.9)
Female	0	0.2	nc	(nc-nc)	Female	54	60.0	89.9	(67.6-117.4)
<u>Leukemia</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	0	1.7	nc	(nc-nc)	<u>All Sites / Types</u>				
Female	1	1.2	nc	(nc-nc)	<u>Uteri Corpus and Uterus, NOS</u>				
<u>Liver and Intrahepatic Bile Ducts</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	1	1.2	nc	(nc-nc)	<u>All Sites / Types</u>				
Female	0	0.3	nc	(nc-nc)	<u>Uteri Corpus and Uterus, NOS</u>				
<u>Lung and Bronchus</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	11	8.6	127.2	(63.4-227.6)	<u>All Sites / Types</u>				
Female	4	7.5	nc	(nc-nc)	<u>Uteri Corpus and Uterus, NOS</u>				

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Merrimac

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2001-2005

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	5	6.1	81.8	(26.4-191.0)	Male	5	3.9	129.0	(41.6-300.9)
Female	3	2.1	nc	(nc-nc)	Female	0	3.2	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	0	1.3	nc	(nc-nc)	Male	0	1.0	nc	(nc-nc)
Female	1	1.0	nc	(nc-nc)	Female	0	0.6	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.2	nc	(nc-nc)	Male	2	3.4	nc	(nc-nc)
Female	28	23.3	120.1	(79.8-173.6)	Female	3	2.8	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity and Pharynx</u>				
Female	1	1.1	nc	(nc-nc)	Male	3	2.5	nc	(nc-nc)
<u>Colon / Rectum</u>					<u>Ovary</u>				
Male	8	9.2	87.0	(37.4-171.3)	Female	2	2.4	nc	(nc-nc)
Female	13	7.7	168.7	(89.7-288.5)	<u>Pancreas</u>				
<u>Esophagus</u>					Male				
Male	3	1.6	nc	(nc-nc)	Male	2	1.8	nc	(nc-nc)
Female	0	0.4	nc	(nc-nc)	Female	1	1.7	nc	(nc-nc)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	0	0.5	nc	(nc-nc)	Male	32	24.2	132.2	(90.4-186.7)
Female	0	0.4	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney and Renal Pelvis</u>					Male				
Male	2	2.9	nc	(nc-nc)	Male	1	1.5	nc	(nc-nc)
Female	2	1.7	nc	(nc-nc)	Female	2	0.8	nc	(nc-nc)
<u>Larynx</u>					<u>Testis</u>				
Male	2	1.0	nc	(nc-nc)	Male	0	0.9	nc	(nc-nc)
Female	0	0.3	nc	(nc-nc)	<u>Thyroid</u>				
<u>Leukemia</u>					Male				
Male	4	2.1	nc	(nc-nc)	Male	0	0.9	nc	(nc-nc)
Female	2	1.5	nc	(nc-nc)	Female	1	3.0	nc	(nc-nc)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	1	1.4	nc	(nc-nc)	Female	8	4.9	161.9	(69.7-319.0)
Female	0	0.4	nc	(nc-nc)	<u>All Sites / Types</u>				
<u>Lung and Bronchus</u>					Male				
Male	11	11.6	95.0	(47.4-170.0)	Male	87	84.2	103.4	(82.8-127.5)
Female	13	10.3	126.3	(67.2-216.0)	Female	82	76.2	107.5	(85.5-133.5)

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Methuen

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2001-2005

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	59	48.9	120.6	(91.8-155.6)	Male	26	28.7	90.5	(59.1-132.6)
Female	23	20.0	115.1	(73.0-172.8)	Female	18	25.0	72.0	(42.7-113.8)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	15	9.2	163.2	(91.3-269.1)	Male	13	7.6	171.8	(91.4-293.7)
Female	8	7.9	100.6	(43.3-198.3)	Female	15	6.1	245.7	(137.4-405.2)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	1	1.4	nc	(nc-nc)	Male	23	25.6	89.7	(56.9-134.6)
Female	162	184.3	87.9	(74.9-102.5)	Female	27	25.6	105.5	(69.5-153.5)
<u>Cervix Uteri</u>					<u>Oral Cavity and Pharynx</u>				
Female	4	7.9	nc	(nc-nc)	Male	22	17.6	124.8	(78.2-189.0)
<u>Colon / Rectum</u>					<u>Ovary</u>				
Male	76	71.6	106.2	(83.7-132.9)	Female	16	20.1	79.8	(45.6-129.6)
Female	82	77.0	106.5	(84.7-132.1)	<u>Pancreas</u>				
<u>Esophagus</u>					Male	17	14.3	119.1	(69.4-190.7)
Male	10	12.2	81.8	(39.2-150.5)	Female	17	16.8	101.2	(58.9-162.0)
Female	8	3.9	203.7	(87.7-401.5)	<u>Prostate</u>				
<u>Hodgkin Lymphoma</u>					Male	191	178.8	106.8	(92.2-123.1)
Male	6	4.0	149.0	(54.4-324.4)	<u>Stomach</u>				
Female	5	3.2	157.2	(50.7-366.9)	Male	10	12.0	83.1	(39.8-152.8)
<u>Kidney and Renal Pelvis</u>					Female	3	8.3	nc	(nc-nc)
Male	29	21.4	135.6	(90.8-194.7)	<u>Testis</u>				
Female	11	14.7	74.8	(37.3-133.9)	Male	11	6.8	162.6	(81.1-291.0)
<u>Larynx</u>					<u>Thyroid</u>				
Male	10	7.5	133.1	(63.7-244.8)	Male	8	6.6	121.9	(52.5-240.1)
Female	3	2.2	nc	(nc-nc)	Female	26	21.2	122.8	(80.2-179.9)
<u>Leukemia</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	12	15.9	75.3	(38.8-131.5)	Female	46	38.8	118.5	(86.8-158.1)
Female	16	13.7	116.8	(66.7-189.6)	<u>All Sites / Types</u>				
<u>Liver and Intrahepatic Bile Ducts</u>					Male	686	639.0	107.4	(99.5-115.7)
Male	8	10.2	78.2	(33.7-154.1)	Female	658	656.2	100.3	(92.8-108.2)
Female	2	4.0	nc	(nc-nc)					
<u>Lung and Bronchus</u>									
Male	86	90.8	94.7	(75.8-117.0)					
Female	95	93.5	101.7	(82.2-124.3)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Middleborough

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2001-2005

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	21	18.1	115.8	(71.6-177.0)	Male	18	11.9	150.7	(89.3-238.2)
Female	9	7.0	128.5	(58.6-244.0)	Female	8	10.3	77.5	(33.4-152.7)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	4	4.0	nc	(nc-nc)	Male	2	3.0	nc	(nc-nc)
Female	5	3.2	154.4	(49.8-360.3)	Female	1	2.1	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.5	nc	(nc-nc)	Male	17	10.4	163.2	(95.0-261.4)
Female	63	73.6	85.6	(65.8-109.6)	Female	12	9.4	128.0	(66.1-223.7)
<u>Cervix Uteri</u>					<u>Oral Cavity and Pharynx</u>				
Female	3	3.5	nc	(nc-nc)	Male	5	7.7	65.0	(20.9-151.7)
<u>Colon / Rectum</u>					<u>Ovary</u>				
Male	37	27.7	133.7	(94.1-184.2)	Female	11	7.8	140.2	(69.9-250.9)
Female	24	27.1	88.6	(56.8-131.9)	<u>Pancreas</u>				
<u>Esophagus</u>					Male	6	5.5	109.2	(39.9-237.8)
Male	6	4.9	123.0	(44.9-267.6)	Female	5	5.8	85.6	(27.6-199.9)
Female	2	1.4	nc	(nc-nc)	<u>Prostate</u>				
<u>Hodgkin Lymphoma</u>					Male	83	72.1	115.1	(91.6-142.6)
Male	4	1.8	nc	(nc-nc)	<u>Stomach</u>				
Female	1	1.4	nc	(nc-nc)	Male	3	4.5	nc	(nc-nc)
<u>Kidney and Renal Pelvis</u>					Female	2	2.9	nc	(nc-nc)
Male	10	8.9	112.3	(53.8-206.6)	<u>Testis</u>				
Female	10	5.5	182.2	(87.2-335.1)	Male	2	3.3	nc	(nc-nc)
<u>Larynx</u>					<u>Thyroid</u>				
Male	4	3.1	nc	(nc-nc)	Male	3	3.0	nc	(nc-nc)
Female	2	0.8	nc	(nc-nc)	Female	15	9.6	155.7	(87.1-256.8)
<u>Leukemia</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	3	6.4	nc	(nc-nc)	Female	12	15.5	77.6	(40.1-135.6)
Female	4	5.1	nc	(nc-nc)	<u>All Sites / Types</u>				
<u>Liver and Intrahepatic Bile Ducts</u>					Male	302	254.2	118.8	(105.8-133.0)
Male	5	4.3	116.4	(37.5-271.5)	Female	248	249.5	99.4	(87.4-112.6)
Female	0	1.4	nc	(nc-nc)					
<u>Lung and Bronchus</u>									
Male	48	34.4	139.4	(102.8-184.8)					
Female	32	33.3	96.2	(65.8-135.8)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Middlefield

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2001-2005

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	0	0.6	nc	(nc-nc)	Male	0	0.4	nc	(nc-nc)
Female	0	0.2	nc	(nc-nc)	Female	0	0.3	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	0	0.1	nc	(nc-nc)	Male	0	0.1	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	Female	0	0.1	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.0	nc	(nc-nc)	Male	0	0.3	nc	(nc-nc)
Female	1	2.1	nc	(nc-nc)	Female	0	0.2	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity and Pharynx</u>				
Female	0	0.1	nc	(nc-nc)	Male	0	0.3	nc	(nc-nc)
<u>Colon / Rectum</u>					<u>Ovary</u>				
Male	0	0.9	nc	(nc-nc)	Female	1	0.2	nc	(nc-nc)
Female	0	0.6	nc	(nc-nc)	<u>Pancreas</u>				
<u>Esophagus</u>					Male	0	0.2	nc	(nc-nc)
Male	0	0.2	nc	(nc-nc)	Female	0	0.1	nc	(nc-nc)
Female	1	0.0	nc	(nc-nc)	<u>Prostate</u>				
<u>Hodgkin Lymphoma</u>					Male	0	2.3	nc	(nc-nc)
Male	0	0.1	nc	(nc-nc)	<u>Stomach</u>				
Female	0	0.0	nc	(nc-nc)	Male	0	0.1	nc	(nc-nc)
<u>Kidney and Renal Pelvis</u>					Female	0	0.1	nc	(nc-nc)
Male	0	0.3	nc	(nc-nc)	<u>Testis</u>				
Female	0	0.1	nc	(nc-nc)	Male	0	0.1	nc	(nc-nc)
<u>Larynx</u>					<u>Thyroid</u>				
Male	0	0.1	nc	(nc-nc)	Male	0	0.1	nc	(nc-nc)
Female	0	0.0	nc	(nc-nc)	Female	0	0.3	nc	(nc-nc)
<u>Leukemia</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	1	0.2	nc	(nc-nc)	Female	0	0.4	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	<u>All Sites / Types</u>				
<u>Liver and Intrahepatic Bile Ducts</u>					Male	5	8.1	61.5	(19.8-143.6)
Male	0	0.1	nc	(nc-nc)	Female	4	6.6	nc	(nc-nc)
Female	0	0.0	nc	(nc-nc)					
<u>Lung and Bronchus</u>									
Male	2	1.1	nc	(nc-nc)					
Female	0	0.9	nc	(nc-nc)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Middleton

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2001-2005

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	8	7.8	103.0	(44.3-202.9)	Male	4	5.5	nc	(nc-nc)
Female	5	2.6	194.5	(62.7-453.8)	Female	4	3.8	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	2	1.9	nc	(nc-nc)	Male	4	1.3	nc	(nc-nc)
Female	2	1.2	nc	(nc-nc)	Female	1	0.8	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.2	nc	(nc-nc)	Male	7	4.7	147.7	(59.2-304.3)
Female	32	28.1	114.0	(77.9-160.9)	Female	4	3.4	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity and Pharynx</u>				
Female	1	1.3	nc	(nc-nc)	Male	1	3.4	nc	(nc-nc)
<u>Colon / Rectum</u>					<u>Ovary</u>				
Male	8	12.0	66.8	(28.8-131.7)	Female	1	3.0	nc	(nc-nc)
Female	9	9.6	93.8	(42.8-178.1)	<u>Pancreas</u>				
<u>Esophagus</u>					Male	1	2.4	nc	(nc-nc)
Male	2	2.1	nc	(nc-nc)	Female	1	2.1	nc	(nc-nc)
Female	0	0.5	nc	(nc-nc)	<u>Prostate</u>				
<u>Hodgkin Lymphoma</u>					Male	33	31.1	106.2	(73.1-149.1)
Male	1	1.0	nc	(nc-nc)	<u>Stomach</u>				
Female	0	0.5	nc	(nc-nc)	Male	3	2.0	nc	(nc-nc)
<u>Kidney and Renal Pelvis</u>					Female	1	1.0	nc	(nc-nc)
Male	1	4.0	nc	(nc-nc)	<u>Testis</u>				
Female	2	2.1	nc	(nc-nc)	Male	0	2.0	nc	(nc-nc)
<u>Larynx</u>					<u>Thyroid</u>				
Male	3	1.3	nc	(nc-nc)	Male	0	1.5	nc	(nc-nc)
Female	0	0.3	nc	(nc-nc)	Female	3	3.5	nc	(nc-nc)
<u>Leukemia</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	4	2.9	nc	(nc-nc)	Female	5	6.1	82.3	(26.5-192.1)
Female	3	1.8	nc	(nc-nc)	<u>All Sites / Types</u>				
<u>Liver and Intrahepatic Bile Ducts</u>					Male	104	111.9	92.9	(75.9-112.6)
Male	1	1.9	nc	(nc-nc)	Female	100	92.9	107.7	(87.6-130.9)
Female	0	0.5	nc	(nc-nc)					
<u>Lung and Bronchus</u>									
Male	12	14.9	80.7	(41.6-141.0)					
Female	20	12.8	156.4	(95.5-241.6)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Milford

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2001-2005

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	38	26.4	143.8	(101.7-197.4)	Male	9	16.6	54.2	(24.7-102.8)
Female	6	10.7	55.9	(20.4-121.7)	Female	17	14.6	116.2	(67.7-186.1)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	6	5.4	110.3	(40.3-240.0)	Male	4	4.2	nc	(nc-nc)
Female	8	4.6	174.2	(75.0-343.3)	Female	3	3.3	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	2	0.8	nc	(nc-nc)	Male	10	14.6	68.4	(32.8-125.9)
Female	95	105.1	90.4	(73.1-110.5)	Female	13	14.1	92.5	(49.2-158.2)
<u>Cervix Uteri</u>					<u>Oral Cavity and Pharynx</u>				
Female	4	4.8	nc	(nc-nc)	Male	7	10.5	66.8	(26.7-137.6)
<u>Colon / Rectum</u>					<u>Ovary</u>				
Male	31	39.6	78.3	(53.2-111.1)	Female	10	11.3	88.2	(42.2-162.2)
Female	36	41.8	86.0	(60.2-119.1)	<u>Pancreas</u>				
<u>Esophagus</u>					Male	6	7.9	76.2	(27.8-165.9)
Male	9	6.9	130.5	(59.6-247.8)	Female	6	9.0	66.5	(24.3-144.7)
Female	2	2.1	nc	(nc-nc)	<u>Prostate</u>				
<u>Hodgkin Lymphoma</u>					Male	90	101.5	88.7	(71.3-109.0)
Male	0	2.5	nc	(nc-nc)	<u>Stomach</u>				
Female	4	1.9	nc	(nc-nc)	Male	10	6.6	152.1	(72.8-279.8)
<u>Kidney and Renal Pelvis</u>					Female	5	4.5	111.2	(35.8-259.6)
Male	12	12.4	96.9	(50.0-169.4)	<u>Testis</u>				
Female	7	8.1	86.5	(34.7-178.2)	Male	3	4.4	nc	(nc-nc)
<u>Larynx</u>					<u>Thyroid</u>				
Male	2	4.3	nc	(nc-nc)	Male	6	4.1	147.3	(53.8-320.5)
Female	2	1.2	nc	(nc-nc)	Female	14	13.0	107.6	(58.8-180.6)
<u>Leukemia</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	8	9.0	88.9	(38.3-175.2)	Female	17	22.1	76.8	(44.7-123.0)
Female	6	7.7	78.4	(28.6-170.7)	<u>All Sites / Types</u>				
<u>Liver and Intrahepatic Bile Ducts</u>					Male	338	359.7	94.0	(84.2-104.5)
Male	9	6.0	151.1	(68.9-286.8)	Female	341	366.4	93.1	(83.5-103.5)
Female	2	2.2	nc	(nc-nc)					
<u>Lung and Bronchus</u>									
Male	56	49.8	112.5	(85.0-146.1)					
Female	47	50.0	94.0	(69.0-125.0)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Millbury

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2001-2005

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	11	15.3	71.9	(35.8-128.6)	Male	5	9.1	54.9	(17.7-128.1)
Female	2	6.2	nc	(nc-nc)	Female	2	7.7	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	1	2.9	nc	(nc-nc)	Male	0	2.4	nc	(nc-nc)
Female	0	2.4	nc	(nc-nc)	Female	1	1.9	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.4	nc	(nc-nc)	Male	8	8.1	99.4	(42.8-195.8)
Female	62	57.7	107.5	(82.4-137.8)	Female	7	7.9	88.7	(35.5-182.7)
<u>Cervix Uteri</u>					<u>Oral Cavity and Pharynx</u>				
Female	3	2.4	nc	(nc-nc)	Male	10	5.7	174.6	(83.6-321.0)
<u>Colon / Rectum</u>					<u>Ovary</u>				
Male	17	22.6	75.3	(43.9-120.6)	Female	6	6.3	95.8	(35.0-208.6)
Female	17	24.0	70.9	(41.3-113.5)	<u>Pancreas</u>				
<u>Esophagus</u>					Male	4	4.5	nc	(nc-nc)
Male	4	3.9	nc	(nc-nc)	Female	3	5.2	nc	(nc-nc)
Female	1	1.2	nc	(nc-nc)	<u>Prostate</u>				
<u>Hodgkin Lymphoma</u>					Male	54	58.3	92.6	(69.6-120.9)
Male	2	1.2	nc	(nc-nc)	<u>Stomach</u>				
Female	0	0.9	nc	(nc-nc)	Male	4	3.8	nc	(nc-nc)
<u>Kidney and Renal Pelvis</u>					Female	1	2.6	nc	(nc-nc)
Male	5	6.8	73.1	(23.6-170.5)	<u>Testis</u>				
Female	5	4.6	109.8	(35.4-256.2)	Male	4	2.0	nc	(nc-nc)
<u>Larynx</u>					<u>Thyroid</u>				
Male	4	2.4	nc	(nc-nc)	Male	2	2.1	nc	(nc-nc)
Female	1	0.7	nc	(nc-nc)	Female	2	6.5	nc	(nc-nc)
<u>Leukemia</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	2	4.9	nc	(nc-nc)	Female	18	12.3	146.1	(86.5-230.9)
Female	4	4.2	nc	(nc-nc)	<u>All Sites / Types</u>				
<u>Liver and Intrahepatic Bile Ducts</u>					Male	193	203.2	95.0	(82.1-109.4)
Male	2	3.3	nc	(nc-nc)	Female	192	204.3	94.0	(81.2-108.3)
Female	1	1.3	nc	(nc-nc)					
<u>Lung and Bronchus</u>									
Male	37	28.6	129.4	(91.1-178.4)					
Female	41	29.0	141.4	(101.5-191.9)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Millis

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2001-2005

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	13	6.6	197.8	(105.2-338.2)	Male	3	4.6	nc	(nc-nc)
Female	4	2.4	nc	(nc-nc)	Female	7	4.0	174.1	(69.8-358.8)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	1	1.6	nc	(nc-nc)	Male	2	1.1	nc	(nc-nc)
Female	0	1.2	nc	(nc-nc)	Female	1	0.7	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	2	0.2	nc	(nc-nc)	Male	5	3.9	127.9	(41.2-298.6)
Female	30	29.1	103.2	(69.6-147.3)	Female	2	3.3	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity and Pharynx</u>				
Female	1	1.4	nc	(nc-nc)	Male	2	3.0	nc	(nc-nc)
<u>Colon / Rectum</u>					<u>Ovary</u>				
Male	10	10.3	97.5	(46.7-179.3)	Female	2	3.0	nc	(nc-nc)
Female	5	9.1	55.1	(17.7-128.5)	<u>Pancreas</u>				
<u>Esophagus</u>					<u>Prostate</u>				
Male	3	1.9	nc	(nc-nc)	Male	35	28.3	123.7	(86.1-172.0)
Female	0	0.5	nc	(nc-nc)	<u>Stomach</u>				
<u>Hodgkin Lymphoma</u>					<u>Testis</u>				
Male	1	0.7	nc	(nc-nc)	Male	2	1.2	nc	(nc-nc)
Female	1	0.5	nc	(nc-nc)	<u>Thyroid</u>				
<u>Kidney and Renal Pelvis</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	5	3.5	144.1	(46.4-336.3)	Female	3	6.2	nc	(nc-nc)
Female	0	2.1	nc	(nc-nc)	<u>All Sites / Types</u>				
<u>Larynx</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	0	1.2	nc	(nc-nc)	Female	3	6.2	nc	(nc-nc)
Female	0	0.3	nc	(nc-nc)	<u>All Sites / Types</u>				
<u>Leukemia</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	5	2.4	210.6	(67.9-491.5)	Male	116	96.5	120.3	(99.4-144.2)
Female	3	1.8	nc	(nc-nc)	Female	93	93.1	99.9	(80.6-122.3)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	1	1.7	nc	(nc-nc)	<u>All Sites / Types</u>				
Female	1	0.5	nc	(nc-nc)	<u>All Sites / Types</u>				
<u>Lung and Bronchus</u>					<u>All Sites / Types</u>				
Male	14	13.0	108.0	(59.0-181.3)	<u>All Sites / Types</u>				
Female	18	12.2	147.3	(87.3-232.8)	<u>All Sites / Types</u>				

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Millville

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2001-2005

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	5	1.8	270.4	(87.1-630.9)	Male	2	1.4	nc	(nc-nc)
Female	1	0.7	nc	(nc-nc)	Female	1	1.3	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	1	0.5	nc	(nc-nc)	Male	0	0.3	nc	(nc-nc)
Female	0	0.4	nc	(nc-nc)	Female	0	0.2	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.1	nc	(nc-nc)	Male	1	1.2	nc	(nc-nc)
Female	9	8.4	107.4	(49.0-203.8)	Female	0	1.0	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity and Pharynx</u>				
Female	0	0.5	nc	(nc-nc)	Male	1	0.8	nc	(nc-nc)
<u>Colon / Rectum</u>					<u>Ovary</u>				
Male	5	2.9	172.3	(55.5-402.0)	Female	2	0.9	nc	(nc-nc)
Female	2	2.7	nc	(nc-nc)	<u>Pancreas</u>				
<u>Esophagus</u>					Male	0	0.6	nc	(nc-nc)
Male	0	0.5	nc	(nc-nc)	Female	0	0.6	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	<u>Prostate</u>				
<u>Hodgkin Lymphoma</u>					Male	5	7.7	65.3	(21.1-152.5)
Male	0	0.2	nc	(nc-nc)	<u>Stomach</u>				
Female	0	0.2	nc	(nc-nc)	Male	0	0.5	nc	(nc-nc)
<u>Kidney and Renal Pelvis</u>					Female	0	0.3	nc	(nc-nc)
Male	0	1.0	nc	(nc-nc)	<u>Testis</u>				
Female	0	0.6	nc	(nc-nc)	Male	0	0.5	nc	(nc-nc)
<u>Larynx</u>					<u>Thyroid</u>				
Male	0	0.3	nc	(nc-nc)	Male	0	0.4	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	Female	1	1.3	nc	(nc-nc)
<u>Leukemia</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	1	0.7	nc	(nc-nc)	Female	3	1.7	nc	(nc-nc)
Female	1	0.6	nc	(nc-nc)	<u>All Sites / Types</u>				
<u>Liver and Intrahepatic Bile Ducts</u>					Male	29	27.4	105.8	(70.8-151.9)
Male	0	0.5	nc	(nc-nc)	Female	27	27.7	97.3	(64.1-141.6)
Female	0	0.1	nc	(nc-nc)					
<u>Lung and Bronchus</u>									
Male	5	3.6	138.4	(44.6-322.9)					
Female	4	3.6	nc	(nc-nc)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Milton

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2001-2005

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	22	30.1	73.1	(45.8-110.6)	Male	31	17.4	178.3	(121.1-253.0)
Female	14	12.2	114.6	(62.6-192.3)	Female	29	15.1	192.7	(129.0-276.7)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	5	5.5	90.9	(29.3-212.2)	Male	3	4.7	nc	(nc-nc)
Female	3	4.8	nc	(nc-nc)	Female	5	3.7	134.4	(43.3-313.7)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.8	nc	(nc-nc)	Male	20	15.5	128.7	(78.6-198.8)
Female	127	113.7	111.7	(93.1-132.9)	Female	21	15.5	135.1	(83.6-206.5)
<u>Cervix Uteri</u>					<u>Oral Cavity and Pharynx</u>				
Female	2	4.7	nc	(nc-nc)	Male	13	10.8	120.3	(64.0-205.7)
<u>Colon / Rectum</u>					<u>Ovary</u>				
Male	52	44.0	118.3	(88.3-155.1)	Female	12	12.3	97.3	(50.2-170.0)
Female	52	47.6	109.3	(81.7-143.4)	<u>Pancreas</u>				
<u>Esophagus</u>					Male	7	8.8	79.7	(31.9-164.2)
Male	6	7.5	80.0	(29.2-174.1)	Female	9	10.3	87.1	(39.7-165.3)
Female	2	2.4	nc	(nc-nc)	<u>Prostate</u>				
<u>Hodgkin Lymphoma</u>					Male	111	109.8	101.1	(83.2-121.8)
Male	3	2.3	nc	(nc-nc)	<u>Stomach</u>				
Female	3	1.8	nc	(nc-nc)	Male	6	7.4	81.2	(29.6-176.7)
<u>Kidney and Renal Pelvis</u>					Female	4	5.1	nc	(nc-nc)
Male	12	13.0	92.0	(47.5-160.8)	<u>Testis</u>				
Female	14	9.0	156.3	(85.4-262.3)	Male	5	3.5	142.6	(46.0-332.8)
<u>Larynx</u>					<u>Thyroid</u>				
Male	4	4.6	nc	(nc-nc)	Male	3	3.8	nc	(nc-nc)
Female	0	1.4	nc	(nc-nc)	Female	15	12.5	119.6	(66.9-197.2)
<u>Leukemia</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	7	9.7	72.4	(29.0-149.1)	Female	19	23.8	79.9	(48.1-124.8)
Female	9	8.4	107.4	(49.0-203.9)	<u>All Sites / Types</u>				
<u>Liver and Intrahepatic Bile Ducts</u>					Male	375	390.2	96.1	(86.6-106.3)
Male	8	6.3	126.6	(54.5-249.5)	Female	435	401.5	108.3	(98.4-119.0)
Female	2	2.5	nc	(nc-nc)					
<u>Lung and Bronchus</u>									
Male	37	55.5	66.6	(46.9-91.8)					
Female	54	56.6	95.4	(71.7-124.5)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Monroe

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2001-2005

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	0	0.1	nc	(nc-nc)	Male	0	0.1	nc	(nc-nc)
Female	0	0.0	nc	(nc-nc)	Female	0	0.1	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	0	0.0	nc	(nc-nc)	Male	0	0.0	nc	(nc-nc)
Female	0	0.0	nc	(nc-nc)	Female	0	0.0	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.0	nc	(nc-nc)	Male	0	0.0	nc	(nc-nc)
Female	1	0.5	nc	(nc-nc)	Female	0	0.1	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity and Pharynx</u>				
Female	0	0.0	nc	(nc-nc)	Male	0	0.0	nc	(nc-nc)
<u>Colon / Rectum</u>					<u>Ovary</u>				
Male	0	0.1	nc	(nc-nc)	Female	0	0.1	nc	(nc-nc)
Female	0	0.2	nc	(nc-nc)	<u>Pancreas</u>				
<u>Esophagus</u>					Male	0	0.0	nc	(nc-nc)
Male	0	0.0	nc	(nc-nc)	Female	0	0.0	nc	(nc-nc)
Female	0	0.0	nc	(nc-nc)	<u>Prostate</u>				
<u>Hodgkin Lymphoma</u>					Male	1	0.4	nc	(nc-nc)
Male	0	0.0	nc	(nc-nc)	<u>Stomach</u>				
Female	0	0.0	nc	(nc-nc)	Male	0	0.0	nc	(nc-nc)
<u>Kidney and Renal Pelvis</u>					Female	0	0.0	nc	(nc-nc)
Male	0	0.0	nc	(nc-nc)	<u>Testis</u>				
Female	0	0.0	nc	(nc-nc)	Male	0	0.0	nc	(nc-nc)
<u>Larynx</u>					<u>Thyroid</u>				
Male	0	0.0	nc	(nc-nc)	Male	0	0.0	nc	(nc-nc)
Female	0	0.0	nc	(nc-nc)	Female	0	0.1	nc	(nc-nc)
<u>Leukemia</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	0	0.0	nc	(nc-nc)	Female	0	0.1	nc	(nc-nc)
Female	0	0.0	nc	(nc-nc)	<u>All Sites / Types</u>				
<u>Liver and Intrahepatic Bile Ducts</u>					Male	2	1.2	nc	(nc-nc)
Male	0	0.0	nc	(nc-nc)	Female	1	1.7	nc	(nc-nc)
Female	0	0.0	nc	(nc-nc)	<u>Lung and Bronchus</u>				
Male	1	0.2	nc	(nc-nc)	<u>Bladder, Urinary</u>				
Female	0	0.2	nc	(nc-nc)	Male	0	0.1	nc	(nc-nc)
<u>Lung and Bronchus</u>					Female	0	0.0	nc	(nc-nc)
Male	1	0.2	nc	(nc-nc)	<u>Brain and Other Nervous System</u>				
Female	0	0.2	nc	(nc-nc)	Male	0	0.0	nc	(nc-nc)
<u>Lung and Bronchus</u>					Female	0	0.0	nc	(nc-nc)
Male	1	0.2	nc	(nc-nc)	<u>Breast</u>				
Female	0	0.2	nc	(nc-nc)	Male	0	0.0	nc	(nc-nc)
<u>Lung and Bronchus</u>					Female	1	0.5	nc	(nc-nc)
Male	1	0.2	nc	(nc-nc)	<u>Cervix Uteri</u>				
Female	0	0.2	nc	(nc-nc)	Female	0	0.0	nc	(nc-nc)
<u>Lung and Bronchus</u>					<u>Colon / Rectum</u>				
Male	1	0.2	nc	(nc-nc)	Male	0	0.1	nc	(nc-nc)
Female	0	0.2	nc	(nc-nc)	Female	0	0.2	nc	(nc-nc)
<u>Lung and Bronchus</u>					<u>Esophagus</u>				
Male	1	0.2	nc	(nc-nc)	Male	0	0.0	nc	(nc-nc)
Female	0	0.2	nc	(nc-nc)	Female	0	0.0	nc	(nc-nc)
<u>Lung and Bronchus</u>					<u>Hodgkin Lymphoma</u>				
Male	1	0.2	nc	(nc-nc)	Male	0	0.0	nc	(nc-nc)
Female	0	0.2	nc	(nc-nc)	Female	0	0.0	nc	(nc-nc)
<u>Lung and Bronchus</u>					<u>Kidney and Renal Pelvis</u>				
Male	1	0.2	nc	(nc-nc)	Male	0	0.0	nc	(nc-nc)
Female	0	0.2	nc	(nc-nc)	Female	0	0.0	nc	(nc-nc)
<u>Lung and Bronchus</u>					<u>Larynx</u>				
Male	1	0.2	nc	(nc-nc)	Male	0	0.0	nc	(nc-nc)
Female	0	0.2	nc	(nc-nc)	Female	0	0.0	nc	(nc-nc)
<u>Lung and Bronchus</u>					<u>Leukemia</u>				
Male	1	0.2	nc	(nc-nc)	Male	0	0.0	nc	(nc-nc)
Female	0	0.2	nc	(nc-nc)	Female	0	0.0	nc	(nc-nc)
<u>Lung and Bronchus</u>					<u>Liver and Intrahepatic Bile Ducts</u>				
Male	1	0.2	nc	(nc-nc)	Male	0	0.0	nc	(nc-nc)
Female	0	0.2	nc	(nc-nc)	Female	0	0.0	nc	(nc-nc)
<u>Lung and Bronchus</u>					<u>Lung and Bronchus</u>				
Male	1	0.2	nc	(nc-nc)	Male	1	0.2	nc	(nc-nc)
Female	0	0.2	nc	(nc-nc)	Female	0	0.2	nc	(nc-nc)

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Monson

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2001-2005

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	7	8.2	85.4	(34.2-176.1)	Male	7	5.4	129.5	(51.9-266.9)
Female	4	3.0	nc	(nc-nc)	Female	3	4.4	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	1	1.8	nc	(nc-nc)	Male	0	1.3	nc	(nc-nc)
Female	0	1.4	nc	(nc-nc)	Female	1	0.9	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.2	nc	(nc-nc)	Male	2	4.7	nc	(nc-nc)
Female	31	32.6	95.0	(64.5-134.8)	Female	8	4.0	199.1	(85.7-392.3)
<u>Cervix Uteri</u>					<u>Oral Cavity and Pharynx</u>				
Female	2	1.5	nc	(nc-nc)	Male	3	3.6	nc	(nc-nc)
<u>Colon / Rectum</u>					<u>Ovary</u>				
Male	13	12.6	103.6	(55.1-177.1)	Female	6	3.5	173.8	(63.5-378.4)
Female	8	11.4	70.2	(30.2-138.3)	<u>Pancreas</u>				
<u>Esophagus</u>					Male	0	2.5	nc	(nc-nc)
Male	1	2.3	nc	(nc-nc)	Female	5	2.5	202.7	(65.3-473.0)
Female	0	0.6	nc	(nc-nc)	<u>Prostate</u>				
<u>Hodgkin Lymphoma</u>					Male	37	33.7	109.9	(77.4-151.5)
Male	2	0.8	nc	(nc-nc)	<u>Stomach</u>				
Female	1	0.6	nc	(nc-nc)	Male	1	2.0	nc	(nc-nc)
<u>Kidney and Renal Pelvis</u>					Female	0	1.2	nc	(nc-nc)
Male	2	4.1	nc	(nc-nc)	<u>Testis</u>				
Female	3	2.4	nc	(nc-nc)	Male	0	1.4	nc	(nc-nc)
<u>Larynx</u>					<u>Thyroid</u>				
Male	0	1.4	nc	(nc-nc)	Male	0	1.4	nc	(nc-nc)
Female	1	0.4	nc	(nc-nc)	Female	4	4.1	nc	(nc-nc)
<u>Leukemia</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	1	2.8	nc	(nc-nc)	Female	4	7.0	nc	(nc-nc)
Female	2	2.1	nc	(nc-nc)	<u>All Sites / Types</u>				
<u>Liver and Intrahepatic Bile Ducts</u>					Male	103	116.1	88.7	(72.4-107.6)
Male	0	2.0	nc	(nc-nc)	Female	102	108.3	94.2	(76.8-114.3)
Female	1	0.6	nc	(nc-nc)					
<u>Lung and Bronchus</u>									
Male	21	15.8	132.8	(82.2-203.0)					
Female	10	14.6	68.7	(32.9-126.3)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Montague

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2001-2005

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	7	9.8	71.1	(28.5-146.5)	Male	4	5.8	nc	(nc-nc)
Female	4	4.0	nc	(nc-nc)	Female	3	4.9	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	5	1.8	277.3	(89.4-647.1)	Male	1	1.5	nc	(nc-nc)
Female	3	1.6	nc	(nc-nc)	Female	1	1.2	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	1	0.3	nc	(nc-nc)	Male	5	5.1	97.5	(31.4-227.5)
Female	27	37.1	72.7	(47.9-105.8)	Female	5	5.1	97.8	(31.5-228.2)
<u>Cervix Uteri</u>					<u>Oral Cavity and Pharynx</u>				
Female	1	1.5	nc	(nc-nc)	Male	5	3.6	138.4	(44.6-322.9)
<u>Colon / Rectum</u>					<u>Ovary</u>				
Male	17	14.5	117.5	(68.4-188.1)	Female	4	4.1	nc	(nc-nc)
Female	13	15.3	85.2	(45.3-145.7)	<u>Pancreas</u>				
<u>Esophagus</u>					Male	5	2.9	173.3	(55.9-404.5)
Male	2	2.5	nc	(nc-nc)	Female	4	3.3	nc	(nc-nc)
Female	0	0.8	nc	(nc-nc)	<u>Prostate</u>				
<u>Hodgkin Lymphoma</u>					Male	31	36.9	84.1	(57.1-119.4)
Male	1	0.8	nc	(nc-nc)	<u>Stomach</u>				
Female	1	0.6	nc	(nc-nc)	Male	2	2.4	nc	(nc-nc)
<u>Kidney and Renal Pelvis</u>					Female	3	1.6	nc	(nc-nc)
Male	4	4.3	nc	(nc-nc)	<u>Testis</u>				
Female	1	3.0	nc	(nc-nc)	Male	3	1.3	nc	(nc-nc)
<u>Larynx</u>					<u>Thyroid</u>				
Male	1	1.5	nc	(nc-nc)	Male	1	1.3	nc	(nc-nc)
Female	2	0.5	nc	(nc-nc)	Female	2	4.1	nc	(nc-nc)
<u>Leukemia</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	2	3.1	nc	(nc-nc)	Female	6	8.0	75.2	(27.4-163.6)
Female	2	2.7	nc	(nc-nc)	<u>All Sites / Types</u>				
<u>Liver and Intrahepatic Bile Ducts</u>					Male	120	129.6	92.6	(76.8-110.7)
Male	0	2.1	nc	(nc-nc)	Female	108	131.7	82.0	(67.3-99.0)
Female	0	0.8	nc	(nc-nc)					
<u>Lung and Bronchus</u>									
Male	18	18.4	97.7	(57.9-154.4)					
Female	14	19.2	73.0	(39.9-122.6)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Monterey

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2001-2005

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	0	1.4	nc	(nc-nc)	Male	3	0.8	nc	(nc-nc)
Female	0	0.4	nc	(nc-nc)	Female	0	0.6	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	0	0.2	nc	(nc-nc)	Male	1	0.2	nc	(nc-nc)
Female	1	0.2	nc	(nc-nc)	Female	0	0.1	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.0	nc	(nc-nc)	Male	0	0.7	nc	(nc-nc)
Female	6	4.4	136.0	(49.7-296.0)	Female	0	0.5	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity and Pharynx</u>				
Female	0	0.2	nc	(nc-nc)	Male	0	0.5	nc	(nc-nc)
<u>Colon / Rectum</u>					<u>Ovary</u>				
Male	2	2.1	nc	(nc-nc)	Female	0	0.5	nc	(nc-nc)
Female	0	1.4	nc	(nc-nc)	<u>Pancreas</u>				
<u>Esophagus</u>					Male	1	0.4	nc	(nc-nc)
Male	1	0.4	nc	(nc-nc)	Female	1	0.3	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	<u>Prostate</u>				
<u>Hodgkin Lymphoma</u>					Male	7	5.8	120.4	(48.2-248.0)
Male	0	0.1	nc	(nc-nc)	<u>Stomach</u>				
Female	0	0.1	nc	(nc-nc)	Male	0	0.3	nc	(nc-nc)
<u>Kidney and Renal Pelvis</u>					Female	0	0.1	nc	(nc-nc)
Male	0	0.7	nc	(nc-nc)	<u>Testis</u>				
Female	0	0.3	nc	(nc-nc)	Male	0	0.1	nc	(nc-nc)
<u>Larynx</u>					<u>Thyroid</u>				
Male	0	0.2	nc	(nc-nc)	Male	0	0.2	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	Female	0	0.5	nc	(nc-nc)
<u>Leukemia</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	0	0.4	nc	(nc-nc)	Female	1	1.0	nc	(nc-nc)
Female	0	0.3	nc	(nc-nc)	<u>All Sites / Types</u>				
<u>Liver and Intrahepatic Bile Ducts</u>					Male	21	19.0	110.2	(68.2-168.5)
Male	0	0.3	nc	(nc-nc)	Female	11	14.3	76.8	(38.3-137.4)
Female	0	0.1	nc	(nc-nc)					
<u>Lung and Bronchus</u>									
Male	4	2.7	nc	(nc-nc)					
Female	1	2.0	nc	(nc-nc)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Montgomery

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2001-2005

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	2	0.8	nc	(nc-nc)	Male	0	0.5	nc	(nc-nc)
Female	1	0.2	nc	(nc-nc)	Female	0	0.4	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	0	0.2	nc	(nc-nc)	Male	0	0.1	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	Female	0	0.1	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.0	nc	(nc-nc)	Male	1	0.5	nc	(nc-nc)
Female	6	2.9	203.7	(74.4-443.4)	Female	0	0.3	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity and Pharynx</u>				
Female	0	0.1	nc	(nc-nc)	Male	0	0.4	nc	(nc-nc)
<u>Colon / Rectum</u>					<u>Ovary</u>				
Male	1	1.2	nc	(nc-nc)	Female	1	0.3	nc	(nc-nc)
Female	1	0.9	nc	(nc-nc)	<u>Pancreas</u>				
<u>Esophagus</u>					Male				
Male	1	0.2	nc	(nc-nc)	Female	0	0.3	nc	(nc-nc)
Female	0	0.0	nc	(nc-nc)	<u>Prostate</u>				
<u>Hodgkin Lymphoma</u>					Male				
Male	0	0.1	nc	(nc-nc)	Female	2	3.5	nc	(nc-nc)
Female	0	0.0	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney and Renal Pelvis</u>					Male				
Male	0	0.4	nc	(nc-nc)	Female	0	0.2	nc	(nc-nc)
Female	0	0.2	nc	(nc-nc)	<u>Testis</u>				
<u>Larynx</u>					Male				
Male	0	0.1	nc	(nc-nc)	Female	1	0.1	nc	(nc-nc)
Female	0	0.0	nc	(nc-nc)	<u>Thyroid</u>				
<u>Leukemia</u>					Male				
Male	1	0.3	nc	(nc-nc)	Female	0	0.1	nc	(nc-nc)
Female	0	0.2	nc	(nc-nc)	<u>Uteri Corpus and Uterus, NOS</u>				
<u>Liver and Intrahepatic Bile Ducts</u>					Female				
Male	1	0.2	nc	(nc-nc)	Male	13	11.7	111.0	(59.1-189.9)
Female	0	0.0	nc	(nc-nc)	Female	11	9.3	118.8	(59.2-212.6)
<u>Lung and Bronchus</u>					<u>All Sites / Types</u>				
Male	2	1.6	nc	(nc-nc)					
Female	1	1.2	nc	(nc-nc)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Mount Washington

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2001-2005

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	0	0.3	nc	(nc-nc)	Male	0	0.1	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	Female	0	0.1	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	0	0.0	nc	(nc-nc)	Male	0	0.0	nc	(nc-nc)
Female	0	0.0	nc	(nc-nc)	Female	0	0.0	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.0	nc	(nc-nc)	Male	0	0.1	nc	(nc-nc)
Female	0	0.7	nc	(nc-nc)	Female	0	0.1	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity and Pharynx</u>				
Female	0	0.0	nc	(nc-nc)	Male	0	0.1	nc	(nc-nc)
<u>Colon / Rectum</u>					<u>Ovary</u>				
Male	0	0.4	nc	(nc-nc)	Female	0	0.1	nc	(nc-nc)
Female	0	0.2	nc	(nc-nc)	<u>Pancreas</u>				
<u>Esophagus</u>					Male	0	0.1	nc	(nc-nc)
Male	0	0.1	nc	(nc-nc)	Female	0	0.1	nc	(nc-nc)
Female	0	0.0	nc	(nc-nc)	<u>Prostate</u>				
<u>Hodgkin Lymphoma</u>					Male	2	1.0	nc	(nc-nc)
Male	0	0.0	nc	(nc-nc)	<u>Stomach</u>				
Female	0	0.0	nc	(nc-nc)	Male	0	0.1	nc	(nc-nc)
<u>Kidney and Renal Pelvis</u>					Female	0	0.0	nc	(nc-nc)
Male	0	0.1	nc	(nc-nc)	<u>Testis</u>				
Female	0	0.1	nc	(nc-nc)	Male	0	0.0	nc	(nc-nc)
<u>Larynx</u>					<u>Thyroid</u>				
Male	0	0.0	nc	(nc-nc)	Male	0	0.0	nc	(nc-nc)
Female	0	0.0	nc	(nc-nc)	Female	0	0.1	nc	(nc-nc)
<u>Leukemia</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	1	0.1	nc	(nc-nc)	Female	0	0.2	nc	(nc-nc)
Female	0	0.0	nc	(nc-nc)	<u>All Sites / Types</u>				
<u>Liver and Intrahepatic Bile Ducts</u>					Male	4	3.3	nc	(nc-nc)
Male	0	0.1	nc	(nc-nc)	Female	1	2.4	nc	(nc-nc)
Female	0	0.0	nc	(nc-nc)					
<u>Lung and Bronchus</u>									
Male	1	0.5	nc	(nc-nc)					
Female	0	0.4	nc	(nc-nc)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Nahant

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2001-2005

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	6	5.8	103.1	(37.6-224.4)	Male	0	3.2	nc	(nc-nc)
Female	3	2.0	nc	(nc-nc)	Female	4	2.4	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	2	0.9	nc	(nc-nc)	Male	3	0.9	nc	(nc-nc)
Female	0	0.7	nc	(nc-nc)	Female	1	0.6	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.2	nc	(nc-nc)	Male	2	2.9	nc	(nc-nc)
Female	21	18.7	112.4	(69.6-171.8)	Female	1	2.5	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity and Pharynx</u>				
Female	0	0.8	nc	(nc-nc)	Male	5	2.0	247.3	(79.7-577.0)
<u>Colon / Rectum</u>					<u>Ovary</u>				
Male	10	8.4	118.9	(56.9-218.6)	Female	3	2.0	nc	(nc-nc)
Female	3	7.7	nc	(nc-nc)	<u>Pancreas</u>				
<u>Esophagus</u>					Male				
Male	2	1.4	nc	(nc-nc)	Male	3	1.7	nc	(nc-nc)
Female	0	0.4	nc	(nc-nc)	Female	1	1.7	nc	(nc-nc)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	0	0.3	nc	(nc-nc)	Male	23	21.0	109.3	(69.3-164.1)
Female	0	0.3	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney and Renal Pelvis</u>					Male				
Male	1	2.4	nc	(nc-nc)	Male	1	1.4	nc	(nc-nc)
Female	1	1.5	nc	(nc-nc)	Female	1	0.8	nc	(nc-nc)
<u>Larynx</u>					<u>Testis</u>				
Male	0	0.9	nc	(nc-nc)	Male	1	0.5	nc	(nc-nc)
Female	0	0.2	nc	(nc-nc)	<u>Thyroid</u>				
<u>Leukemia</u>					Male				
Male	4	1.8	nc	(nc-nc)	Male	0	0.6	nc	(nc-nc)
Female	1	1.3	nc	(nc-nc)	Female	2	2.0	nc	(nc-nc)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	0	1.2	nc	(nc-nc)	Female	2	4.0	nc	(nc-nc)
Female	0	0.4	nc	(nc-nc)	<u>All Sites / Types</u>				
<u>Lung and Bronchus</u>					Male				
Male	8	10.6	75.2	(32.4-148.2)	Male	76	73.8	103.0	(81.2-129.0)
Female	14	9.3	151.2	(82.6-253.7)	Female	63	65.1	96.7	(74.3-123.7)

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Nantucket

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2001-2005

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	11	8.6	128.1	(63.9-229.2)	Male	14	5.9	237.2	(129.5-397.9)
Female	7	3.2	221.2	(88.6-455.9)	Female	6	4.9	122.8	(44.9-267.4)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	4	1.9	nc	(nc-nc)	Male	0	1.4	nc	(nc-nc)
Female	2	1.5	nc	(nc-nc)	Female	4	1.0	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.2	nc	(nc-nc)	Male	5	5.1	98.6	(31.8-230.1)
Female	48	33.3	144.1	(106.2-191.1)	Female	4	4.2	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity and Pharynx</u>				
Female	3	1.7	nc	(nc-nc)	Male	1	3.6	nc	(nc-nc)
<u>Colon / Rectum</u>					<u>Ovary</u>				
Male	17	13.1	129.4	(75.3-207.1)	Female	5	3.5	141.9	(45.7-331.3)
Female	20	11.9	167.8	(102.5-259.2)	<u>Pancreas</u>				
<u>Esophagus</u>					Male	3	2.6	nc	(nc-nc)
Male	1	2.3	nc	(nc-nc)	Female	3	2.6	nc	(nc-nc)
Female	0	0.6	nc	(nc-nc)	<u>Prostate</u>				
<u>Hodgkin Lymphoma</u>					Male	65	34.5	188.6	(145.5-240.4)
Male	1	1.0	nc	(nc-nc)	<u>Stomach</u>				
Female	0	0.7	nc	(nc-nc)	Male	1	2.2	nc	(nc-nc)
<u>Kidney and Renal Pelvis</u>					Female	0	1.3	nc	(nc-nc)
Male	1	4.3	nc	(nc-nc)	<u>Testis</u>				
Female	1	2.5	nc	(nc-nc)	Male	4	2.0	nc	(nc-nc)
<u>Larynx</u>					<u>Thyroid</u>				
Male	0	1.5	nc	(nc-nc)	Male	2	1.6	nc	(nc-nc)
Female	0	0.4	nc	(nc-nc)	Female	3	4.7	nc	(nc-nc)
<u>Leukemia</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	1	3.0	nc	(nc-nc)	Female	3	6.9	nc	(nc-nc)
Female	3	2.3	nc	(nc-nc)	<u>All Sites / Types</u>				
<u>Liver and Intrahepatic Bile Ducts</u>					Male	150	122.2	122.7	(103.9-144.0)
Male	1	2.1	nc	(nc-nc)	Female	133	113.1	117.6	(98.5-139.4)
Female	2	0.6	nc	(nc-nc)					
<u>Lung and Bronchus</u>									
Male	13	16.6	78.4	(41.7-134.1)					
Female	9	15.3	59.0	(26.9-111.9)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Natick

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2001-2005

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	32	35.0	91.4	(62.5-129.1)	Male	41	21.2	193.7	(139.0-262.8)
Female	17	14.1	120.8	(70.4-193.5)	Female	17	18.6	91.2	(53.1-146.0)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	11	6.7	163.2	(81.3-292.0)	Male	7	5.5	127.3	(51.0-262.3)
Female	9	5.8	155.0	(70.7-294.2)	Female	4	4.3	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	1.0	nc	(nc-nc)	Male	18	18.6	96.6	(57.2-152.7)
Female	147	136.9	107.4	(90.7-126.2)	Female	16	18.2	88.0	(50.3-142.9)
<u>Cervix Uteri</u>					<u>Oral Cavity and Pharynx</u>				
Female	6	6.1	98.9	(36.1-215.4)	Male	12	13.2	90.9	(46.9-158.8)
<u>Colon / Rectum</u>					<u>Ovary</u>				
Male	56	51.7	108.3	(81.8-140.6)	Female	13	14.7	88.5	(47.1-151.4)
Female	55	53.8	102.3	(77.0-133.1)	<u>Pancreas</u>				
<u>Esophagus</u>					Male	9	10.3	87.2	(39.8-165.5)
Male	11	9.0	122.3	(61.0-218.8)	Female	9	11.7	76.8	(35.0-145.8)
Female	2	2.7	nc	(nc-nc)	<u>Prostate</u>				
<u>Hodgkin Lymphoma</u>					Male	140	135.3	103.5	(87.0-122.1)
Male	2	2.8	nc	(nc-nc)	<u>Stomach</u>				
Female	1	2.3	nc	(nc-nc)	Male	6	8.6	69.9	(25.5-152.2)
<u>Kidney and Renal Pelvis</u>					Female	5	5.7	87.6	(28.2-204.4)
Male	13	16.0	81.5	(43.4-139.4)	<u>Testis</u>				
Female	12	10.6	113.2	(58.4-197.8)	Male	8	5.0	159.9	(68.9-315.1)
<u>Larynx</u>					<u>Thyroid</u>				
Male	9	5.6	160.4	(73.2-304.5)	Male	6	5.0	120.2	(43.9-261.7)
Female	1	1.6	nc	(nc-nc)	Female	23	16.3	140.8	(89.2-211.3)
<u>Leukemia</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	11	11.4	96.3	(48.0-172.2)	Female	24	29.1	82.6	(52.9-122.9)
Female	13	9.7	133.7	(71.1-228.6)	<u>All Sites / Types</u>				
<u>Liver and Intrahepatic Bile Ducts</u>					Male	487	469.9	103.6	(94.6-113.3)
Male	5	7.6	65.6	(21.2-153.2)	Female	494	475.6	103.9	(94.9-113.4)
Female	1	2.8	nc	(nc-nc)					
<u>Lung and Bronchus</u>									
Male	58	66.4	87.4	(66.4-113.0)					
Female	84	66.7	125.9	(100.4-155.9)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Needham

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2001-2005

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	32	36.9	86.7	(59.3-122.5)	Male	25	20.8	120.3	(77.8-177.6)
Female	14	15.2	92.4	(50.5-155.0)	Female	24	17.6	136.8	(87.6-203.5)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	11	6.4	171.0	(85.2-306.0)	Male	4	5.7	nc	(nc-nc)
Female	7	5.6	124.3	(49.8-256.1)	Female	6	4.6	131.4	(48.0-285.9)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	1	1.0	nc	(nc-nc)	Male	15	18.6	80.6	(45.1-132.9)
Female	163	134.8	120.9	(103.0-140.9)	Female	33	18.9	174.4	(120.0-244.9)
<u>Cervix Uteri</u>					<u>Oral Cavity and Pharynx</u>				
Female	4	5.4	nc	(nc-nc)	Male	9	12.9	69.8	(31.9-132.5)
<u>Colon / Rectum</u>					<u>Ovary</u>				
Male	43	53.5	80.3	(58.1-108.2)	Female	13	14.7	88.5	(47.1-151.3)
Female	60	59.8	100.3	(76.6-129.2)	<u>Pancreas</u>				
<u>Esophagus</u>					Male	11	10.7	102.6	(51.1-183.6)
Male	5	9.1	55.0	(17.7-128.3)	Female	13	12.9	100.5	(53.4-171.8)
Female	3	3.0	nc	(nc-nc)	<u>Prostate</u>				
<u>Hodgkin Lymphoma</u>					Male	153	133.6	114.5	(97.1-134.1)
Male	3	2.4	nc	(nc-nc)	<u>Stomach</u>				
Female	2	1.9	nc	(nc-nc)	Male	4	9.0	nc	(nc-nc)
<u>Kidney and Renal Pelvis</u>					Female	2	6.5	nc	(nc-nc)
Male	14	15.7	89.3	(48.8-149.8)	<u>Testis</u>				
Female	10	10.8	93.0	(44.5-171.1)	Male	3	3.7	nc	(nc-nc)
<u>Larynx</u>					<u>Thyroid</u>				
Male	3	5.6	nc	(nc-nc)	Male	9	4.4	204.6	(93.4-388.4)
Female	0	1.6	nc	(nc-nc)	Female	18	13.9	129.1	(76.5-204.1)
<u>Leukemia</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	12	11.6	103.5	(53.4-180.8)	Female	20	28.4	70.5	(43.1-108.9)
Female	8	10.3	77.7	(33.5-153.2)	<u>All Sites / Types</u>				
<u>Liver and Intrahepatic Bile Ducts</u>					Male	443	472.4	93.8	(85.2-102.9)
Male	6	7.6	79.4	(29.0-172.9)	Female	518	484.5	106.9	(97.9-116.5)
Female	3	3.1	nc	(nc-nc)					
<u>Lung and Bronchus</u>									
Male	51	67.7	75.3	(56.1-99.0)					
Female	57	68.3	83.5	(63.2-108.2)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

New Ashford

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2001-2005

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	0	0.2	nc	(nc-nc)	Male	0	0.2	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	Female	0	0.1	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	0	0.1	nc	(nc-nc)	Male	0	0.0	nc	(nc-nc)
Female	0	0.0	nc	(nc-nc)	Female	0	0.0	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.0	nc	(nc-nc)	Male	1	0.1	nc	(nc-nc)
Female	2	0.9	nc	(nc-nc)	Female	0	0.1	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity and Pharynx</u>				
Female	0	0.0	nc	(nc-nc)	Male	0	0.1	nc	(nc-nc)
<u>Colon / Rectum</u>					<u>Ovary</u>				
Male	0	0.4	nc	(nc-nc)	Female	0	0.1	nc	(nc-nc)
Female	0	0.3	nc	(nc-nc)	<u>Pancreas</u>				
<u>Esophagus</u>					Male				
Male	0	0.1	nc	(nc-nc)	Male	0	0.1	nc	(nc-nc)
Female	0	0.0	nc	(nc-nc)	Female	0	0.1	nc	(nc-nc)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	0	0.0	nc	(nc-nc)	Male	3	0.9	nc	(nc-nc)
Female	0	0.0	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney and Renal Pelvis</u>					Male				
Male	0	0.1	nc	(nc-nc)	Male	0	0.1	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	Female	0	0.0	nc	(nc-nc)
<u>Larynx</u>					<u>Testis</u>				
Male	0	0.0	nc	(nc-nc)	Male	0	0.0	nc	(nc-nc)
Female	0	0.0	nc	(nc-nc)	<u>Thyroid</u>				
<u>Leukemia</u>					Male				
Male	0	0.1	nc	(nc-nc)	Male	0	0.0	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	Female	0	0.1	nc	(nc-nc)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	0	0.1	nc	(nc-nc)	Female	1	0.2	nc	(nc-nc)
Female	0	0.0	nc	(nc-nc)	<u>All Sites / Types</u>				
<u>Lung and Bronchus</u>					Male				
Male	0	0.5	nc	(nc-nc)	Male	5	3.3	150.2	(48.4-350.4)
Female	0	0.4	nc	(nc-nc)	Female	3	2.9	nc	(nc-nc)

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

New Bedford

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2001-2005

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	115	104.6	110.0	(90.8-132.0)	Male	23	59.6	38.6	(24.4-57.9)
Female	42	44.3	94.8	(68.3-128.2)	Female	27	53.3	50.7	(33.4-73.8)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	26	19.0	137.0	(89.5-200.8)	Male	15	16.0	93.7	(52.4-154.6)
Female	13	17.2	75.7	(40.3-129.5)	Female	15	13.5	111.4	(62.3-183.8)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	3	2.9	nc	(nc-nc)	Male	40	53.5	74.7	(53.4-101.7)
Female	339	390.2	86.9	(77.9-96.6)	Female	46	56.2	81.9	(59.9-109.2)
<u>Cervix Uteri</u>					<u>Oral Cavity and Pharynx</u>				
Female	22	16.3	134.7	(84.4-203.9)	Male	41	36.0	113.9	(81.7-154.5)
Female					Female	21	19.9	105.5	(65.3-161.3)
<u>Colon / Rectum</u>					<u>Ovary</u>				
Male	135	151.2	89.3	(74.8-105.7)	Female	51	43.0	118.7	(88.3-156.0)
Female	166	170.9	97.1	(82.9-113.1)	<u>Pancreas</u>				
<u>Esophagus</u>					Male	37	30.2	122.3	(86.1-168.6)
Male	25	25.7	97.4	(63.0-143.8)	Female	44	37.4	117.7	(85.5-158.0)
Female	6	8.7	68.8	(25.1-149.8)	<u>Prostate</u>				
<u>Hodgkin Lymphoma</u>					Male	360	379.6	94.8	(85.3-105.2)
Male	7	8.6	81.9	(32.8-168.7)	<u>Stomach</u>				
Female	10	7.1	140.7	(67.4-258.8)	Male	44	25.6	172.1	(125.0-231.0)
<u>Kidney and Renal Pelvis</u>					Female	28	18.4	152.1	(101.0-219.8)
Male	48	44.3	108.3	(79.8-143.6)	<u>Testis</u>				
Female	38	31.9	119.2	(84.3-163.6)	Male	13	14.2	91.4	(48.6-156.3)
<u>Larynx</u>					<u>Thyroid</u>				
Male	20	15.8	126.8	(77.4-195.8)	Male	12	13.3	90.5	(46.7-158.2)
Female	4	4.8	nc	(nc-nc)	Female	27	43.9	61.5	(40.5-89.5)
<u>Leukemia</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	39	33.7	115.6	(82.2-158.0)	Female	86	82.9	103.7	(82.9-128.1)
Female	22	30.2	72.9	(45.7-110.3)	<u>All Sites / Types</u>				
<u>Liver and Intrahepatic Bile Ducts</u>					Male	1359	1349.6	100.7	(95.4-106.2)
Male	35	21.1	165.7	(115.4-230.5)	Female	1313	1421.1	92.4	(87.5-97.5)
Female	14	8.9	156.9	(85.7-263.3)					
<u>Lung and Bronchus</u>									
Male	235	193.3	121.6	(106.5-138.2)					
Female	182	205.5	88.6	(76.2-102.4)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

New Braintree

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2001-2005

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	1	0.8	nc	(nc-nc)	Male	1	0.6	nc	(nc-nc)
Female	0	0.3	nc	(nc-nc)	Female	1	0.5	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	0	0.2	nc	(nc-nc)	Male	1	0.1	nc	(nc-nc)
Female	0	0.2	nc	(nc-nc)	Female	0	0.1	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.0	nc	(nc-nc)	Male	1	0.5	nc	(nc-nc)
Female	3	3.5	nc	(nc-nc)	Female	0	0.4	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity and Pharynx</u>				
Female	1	0.2	nc	(nc-nc)	Male	0	0.4	nc	(nc-nc)
<u>Colon / Rectum</u>					<u>Ovary</u>				
Male	1	1.3	nc	(nc-nc)	Female	0	0.4	nc	(nc-nc)
Female	0	1.2	nc	(nc-nc)	<u>Pancreas</u>				
<u>Esophagus</u>					Male				
Male	0	0.2	nc	(nc-nc)	Male	1	0.3	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	Female	0	0.3	nc	(nc-nc)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	0	0.1	nc	(nc-nc)	Male	6	3.3	180.7	(66.0-393.3)
Female	0	0.1	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney and Renal Pelvis</u>					Male				
Male	0	0.4	nc	(nc-nc)	Male	0	0.2	nc	(nc-nc)
Female	0	0.3	nc	(nc-nc)	Female	0	0.1	nc	(nc-nc)
<u>Larynx</u>					<u>Testis</u>				
Male	0	0.1	nc	(nc-nc)	Male	0	0.2	nc	(nc-nc)
Female	0	0.0	nc	(nc-nc)	<u>Thyroid</u>				
<u>Leukemia</u>					Male				
Male	0	0.3	nc	(nc-nc)	Male	0	0.2	nc	(nc-nc)
Female	0	0.2	nc	(nc-nc)	Female	1	0.5	nc	(nc-nc)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	0	0.2	nc	(nc-nc)	Female	0	0.7	nc	(nc-nc)
Female	1	0.1	nc	(nc-nc)	<u>All Sites / Types</u>				
<u>Lung and Bronchus</u>					Male				
Male	0	1.6	nc	(nc-nc)	Male	12	12.1	99.1	(51.1-173.1)
Female	1	1.5	nc	(nc-nc)	Female	9	11.4	78.8	(36.0-149.6)

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

New Marlborough

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2001-2005

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	0	2.0	nc	(nc-nc)	Male	0	1.2	nc	(nc-nc)
Female	0	0.6	nc	(nc-nc)	Female	0	0.8	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	0	0.4	nc	(nc-nc)	Male	0	0.3	nc	(nc-nc)
Female	0	0.3	nc	(nc-nc)	Female	0	0.2	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.1	nc	(nc-nc)	Male	1	1.1	nc	(nc-nc)
Female	5	6.2	81.2	(26.2-189.4)	Female	3	0.8	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity and Pharynx</u>				
Female	1	0.3	nc	(nc-nc)	Male	0	0.8	nc	(nc-nc)
<u>Colon / Rectum</u>					<u>Ovary</u>				
Male	2	3.0	nc	(nc-nc)	Female	0	0.7	nc	(nc-nc)
Female	4	2.2	nc	(nc-nc)	<u>Pancreas</u>				
<u>Esophagus</u>					Male	0	0.6	nc	(nc-nc)
Male	0	0.5	nc	(nc-nc)	Female	0	0.5	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	<u>Prostate</u>				
<u>Hodgkin Lymphoma</u>					Male	4	8.1	nc	(nc-nc)
Male	0	0.2	nc	(nc-nc)	<u>Stomach</u>				
Female	0	0.1	nc	(nc-nc)	Male	0	0.5	nc	(nc-nc)
<u>Kidney and Renal Pelvis</u>					Female	0	0.2	nc	(nc-nc)
Male	1	0.9	nc	(nc-nc)	<u>Testis</u>				
Female	0	0.5	nc	(nc-nc)	Male	1	0.2	nc	(nc-nc)
<u>Larynx</u>					<u>Thyroid</u>				
Male	0	0.3	nc	(nc-nc)	Male	0	0.3	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	Female	1	0.7	nc	(nc-nc)
<u>Leukemia</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	0	0.6	nc	(nc-nc)	Female	0	1.3	nc	(nc-nc)
Female	0	0.4	nc	(nc-nc)	<u>All Sites / Types</u>				
<u>Liver and Intrahepatic Bile Ducts</u>					Male	12	27.4	43.8	(22.6-76.4)
Male	1	0.5	nc	(nc-nc)	Female	20	20.8	96.2	(58.7-148.6)
Female	0	0.1	nc	(nc-nc)					
<u>Lung and Bronchus</u>									
Male	1	3.9	nc	(nc-nc)					
Female	3	3.0	nc	(nc-nc)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

New Salem

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2001-2005

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	0	1.1	nc	(nc-nc)	Male	0	0.7	nc	(nc-nc)
Female	1	0.3	nc	(nc-nc)	Female	0	0.5	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	0	0.2	nc	(nc-nc)	Male	0	0.2	nc	(nc-nc)
Female	0	0.2	nc	(nc-nc)	Female	0	0.1	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.0	nc	(nc-nc)	Male	0	0.6	nc	(nc-nc)
Female	2	3.9	nc	(nc-nc)	Female	0	0.4	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity and Pharynx</u>				
Female	0	0.2	nc	(nc-nc)	Male	0	0.5	nc	(nc-nc)
<u>Colon / Rectum</u>					<u>Ovary</u>				
Male	4	1.7	nc	(nc-nc)	Female	1	0.4	nc	(nc-nc)
Female	1	1.2	nc	(nc-nc)	<u>Pancreas</u>				
<u>Esophagus</u>					Male	0	0.3	nc	(nc-nc)
Male	0	0.3	nc	(nc-nc)	Female	0	0.3	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	<u>Prostate</u>				
<u>Hodgkin Lymphoma</u>					Male	4	4.8	nc	(nc-nc)
Male	0	0.1	nc	(nc-nc)	<u>Stomach</u>				
Female	1	0.1	nc	(nc-nc)	Male	0	0.3	nc	(nc-nc)
<u>Kidney and Renal Pelvis</u>					Female	0	0.1	nc	(nc-nc)
Male	0	0.6	nc	(nc-nc)	<u>Testis</u>				
Female	0	0.3	nc	(nc-nc)	Male	0	0.1	nc	(nc-nc)
<u>Larynx</u>					<u>Thyroid</u>				
Male	0	0.2	nc	(nc-nc)	Male	0	0.2	nc	(nc-nc)
Female	0	0.0	nc	(nc-nc)	Female	2	0.5	nc	(nc-nc)
<u>Leukemia</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	0	0.4	nc	(nc-nc)	Female	0	0.8	nc	(nc-nc)
Female	0	0.2	nc	(nc-nc)	<u>All Sites / Types</u>				
<u>Liver and Intrahepatic Bile Ducts</u>					Male	12	16.0	75.1	(38.8-131.2)
Male	0	0.3	nc	(nc-nc)	Female	12	12.2	98.5	(50.8-172.1)
Female	0	0.1	nc	(nc-nc)					
<u>Lung and Bronchus</u>									
Male	3	2.2	nc	(nc-nc)					
Female	3	1.5	nc	(nc-nc)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;